ATE145337T1
(de)
*
|
1988-05-02 |
1996-12-15 |
Phanos Tech Inc |
Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
DK0465529T3
(da)
*
|
1989-03-21 |
1998-10-05 |
Vical Inc |
Ekspression af exogene polynukleotidsekvenser i et hvirveldyr
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
US6228844B1
(en)
|
1991-11-12 |
2001-05-08 |
Vical Incorporated |
Stimulating vascular growth by administration of DNA sequences encoding VEGF
|
US6706694B1
(en)
|
1990-03-21 |
2004-03-16 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5256641A
(en)
*
|
1990-11-01 |
1993-10-26 |
State Of Oregon |
Covalent polar lipid-peptide conjugates for immunological targeting
|
US5543389A
(en)
*
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization |
Covalent polar lipid-peptide conjugates for use in salves
|
US5827819A
(en)
*
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
US6156304A
(en)
*
|
1990-12-20 |
2000-12-05 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Gene transfer for studying and treating a connective tissue of a mammalian host
|
US7202225B1
(en)
*
|
1993-10-15 |
2007-04-10 |
Emanuele R Martin |
Therapeutic delivery compositions and methods of use thereof
|
US20020123476A1
(en)
*
|
1991-03-19 |
2002-09-05 |
Emanuele R. Martin |
Therapeutic delivery compositions and methods of use thereof
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5858784A
(en)
*
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
US6627615B1
(en)
|
1991-12-17 |
2003-09-30 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
US5756353A
(en)
*
|
1991-12-17 |
1998-05-26 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol-and liposome-based delivery
|
AU3467193A
(en)
|
1991-12-17 |
1993-07-19 |
Regents Of The University Of California, The |
Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR)
|
JPH07503372A
(ja)
*
|
1992-01-23 |
1995-04-13 |
バイカル・インコーポレイテッド |
生体外遺伝子導入
|
US5885970A
(en)
*
|
1992-03-16 |
1999-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US6113946A
(en)
*
|
1992-04-03 |
2000-09-05 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system comprising dendrimer polycations
|
EP1236473A3
(fr)
*
|
1992-04-03 |
2003-01-15 |
The Regents Of The University Of California |
Systeme de livraison d'un polynucleotide a assemblage autonome
|
US5792751A
(en)
*
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
US20020108136A1
(en)
*
|
1997-03-21 |
2002-08-08 |
Sri |
Transgenic animals produced by homologous sequence targeting
|
WO1993024640A2
(fr)
*
|
1992-06-04 |
1993-12-09 |
The Regents Of The University Of California |
PROCEDES ET COMPOSITIONS UTILISES DANS UNE THERAPIE GENIQUE $i(IN VIVO)
|
US6806084B1
(en)
*
|
1992-06-04 |
2004-10-19 |
The Regents Of The University Of California |
Methods for compositions for in vivo gene delivery
|
RU2157239C2
(ru)
*
|
1992-07-13 |
2000-10-10 |
Юкэрион, Инк. |
Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики
|
US7105574B1
(en)
|
1999-03-26 |
2006-09-12 |
Vical Incorporated |
Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
|
US5334761A
(en)
*
|
1992-08-28 |
1994-08-02 |
Life Technologies, Inc. |
Cationic lipids
|
US5523389A
(en)
*
|
1992-09-29 |
1996-06-04 |
Isis Pharmaceuticals, Inc. |
Inhibitors of human immunodeficiency virus
|
US5329029A
(en)
*
|
1992-11-05 |
1994-07-12 |
Wan Barbara Y |
Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
|
US5552155A
(en)
*
|
1992-12-04 |
1996-09-03 |
The Liposome Company, Inc. |
Fusogenic lipsomes and methods for making and using same
|
US5705655A
(en)
*
|
1992-12-17 |
1998-01-06 |
Megabios Corporation |
Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
|
US5631237A
(en)
*
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
AU6358594A
(en)
*
|
1993-03-09 |
1994-09-26 |
Middlesex Sciences, Inc. |
Macromolecular microparticles and methods of production
|
EP0702516A4
(fr)
*
|
1993-06-01 |
1998-04-22 |
Life Technologies Inc |
Immunisation genetique a l'aide de lipides cationiques
|
WO1995002698A1
(fr)
*
|
1993-07-12 |
1995-01-26 |
Life Technologies, Inc. |
Compositions et procedes servant a transfecter des cellules eucaryotes
|
US5563111A
(en)
*
|
1993-08-03 |
1996-10-08 |
Kao Corporation |
Agricultural chemical composition comprising amine surfactants with at least one ester or amide linkage
|
US6348449B1
(en)
|
1993-09-21 |
2002-02-19 |
The Trustees Of The University Of Pennsylvania |
Methods of inducing mucosal immunity
|
CA2176715A1
(fr)
*
|
1993-11-24 |
1995-06-01 |
Timothy D. Heath |
Derives amphiphiles de guanidine
|
US5665879A
(en)
*
|
1993-11-24 |
1997-09-09 |
Megabios Corporation |
Amphiphilic derivatives of piperazine
|
KR960705798A
(ko)
*
|
1993-11-24 |
1996-11-08 |
벤자민 에프 맥그로우 |
피페라진의 양쪽친화성 유도체(amphiphilic derivatives of piperazine)
|
US6613351B1
(en)
*
|
1993-12-20 |
2003-09-02 |
Biotech Tools S.A. |
Compound capable of introducing at least one molecule into a cell
|
US5674908A
(en)
|
1993-12-20 |
1997-10-07 |
Life Technologies, Inc. |
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
|
US6057299A
(en)
*
|
1994-01-13 |
2000-05-02 |
Calydon, Inc. |
Tissue-specific enhancer active in prostate
|
US5830686A
(en)
*
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
US5928944A
(en)
*
|
1994-02-04 |
1999-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of adenoviral-medicated cell transfection
|
US6075012A
(en)
*
|
1994-02-11 |
2000-06-13 |
Life Technologies, Inc. |
Reagents for intracellular delivery of macromolecules
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US5962427A
(en)
|
1994-02-18 |
1999-10-05 |
The Regent Of The University Of Michigan |
In vivo gene transfer methods for wound healing
|
US5942496A
(en)
|
1994-02-18 |
1999-08-24 |
The Regent Of The University Of Michigan |
Methods and compositions for multiple gene transfer into bone cells
|
US5763416A
(en)
|
1994-02-18 |
1998-06-09 |
The Regent Of The University Of Michigan |
Gene transfer into bone cells and tissues
|
US6074840A
(en)
|
1994-02-18 |
2000-06-13 |
The Regents Of The University Of Michigan |
Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5651981A
(en)
*
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
US5739118A
(en)
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
WO1995027496A1
(fr)
*
|
1994-04-07 |
1995-10-19 |
Proteinix Company |
Polypeptide intestinal vasoactif
|
AU2589095A
(en)
*
|
1994-05-16 |
1995-12-05 |
Washington University |
Cell membrane fusion composition and method
|
EP0807116A4
(fr)
*
|
1994-06-22 |
1998-01-07 |
Megabios Corp |
Amphiphiles cationiques
|
US5777153A
(en)
*
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
FR2722506B1
(fr)
*
|
1994-07-13 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucleiques, preparation et utilisations
|
DE4426429A1
(de)
*
|
1994-07-26 |
1996-02-01 |
Boehringer Ingelheim Int |
Verfahren zum Einführen von DNA in höhere eukaryotische Zellen
|
US7592317B1
(en)
*
|
1994-08-11 |
2009-09-22 |
The University Of Chicago |
Constitutive gene expression in conjuction with ionizing radiation
|
AUPM747694A0
(en)
*
|
1994-08-16 |
1994-09-08 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids and peptides
|
US5892071A
(en)
*
|
1994-09-30 |
1999-04-06 |
The Reagents Of The University Of California |
Cationic transport reagents
|
US5527928A
(en)
*
|
1994-09-30 |
1996-06-18 |
Nantz; Michael H. |
Cationic transport reagents
|
US5837533A
(en)
*
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
US5753613A
(en)
*
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
ATE219660T1
(de)
*
|
1994-09-30 |
2002-07-15 |
Inex Pharmaceuticals Corp |
Mittel zum einbringen polyanionischer materialien in zellen
|
US6911216B1
(en)
|
1994-10-12 |
2005-06-28 |
Genzyme Corporation |
Targeted delivery via biodegradable polymers
|
US5641665A
(en)
*
|
1994-11-28 |
1997-06-24 |
Vical Incorporated |
Plasmids suitable for IL-2 expression
|
US5840710A
(en)
*
|
1994-12-09 |
1998-11-24 |
Genzyme Corporation |
Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
|
US6071890A
(en)
*
|
1994-12-09 |
2000-06-06 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
|
US5948767A
(en)
*
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
US5650096A
(en)
*
|
1994-12-09 |
1997-07-22 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5939401A
(en)
*
|
1994-12-09 |
1999-08-17 |
Genzyme Corporation |
Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
|
US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5910487A
(en)
*
|
1994-12-09 |
1999-06-08 |
Genzyme Corporation |
Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
|
US5767099A
(en)
*
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
US5719131A
(en)
*
|
1994-12-09 |
1998-02-17 |
Genzyme Corporation |
Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
|
US6331524B1
(en)
|
1994-12-09 |
2001-12-18 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
|
US5747471A
(en)
*
|
1994-12-09 |
1998-05-05 |
Genzyme Corporation |
Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
|
US6630455B1
(en)
|
1995-01-13 |
2003-10-07 |
Vanderbilt University |
Methods for inducing mucosal immune responses
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5929043A
(en)
*
|
1995-01-31 |
1999-07-27 |
Pangene Corporation |
Recombinase mediated DNA therapies
|
US5830430A
(en)
*
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
EA001616B1
(ru)
|
1995-02-28 |
2001-06-25 |
Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ |
Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
|
US6752987B1
(en)
|
1995-02-28 |
2004-06-22 |
The Regents Of The University Of California |
Adenovirus encoding human adenylylcyclase (AC) VI
|
US20030148968A1
(en)
*
|
1995-02-28 |
2003-08-07 |
Hammond H. Kirk |
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
|
US5962428A
(en)
*
|
1995-03-30 |
1999-10-05 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
US20020183288A1
(en)
*
|
1995-04-03 |
2002-12-05 |
Bone Care International, Inc. |
Method for treating and preventing hyperparathyroidism
|
US6242434B1
(en)
*
|
1997-08-08 |
2001-06-05 |
Bone Care International, Inc. |
24-hydroxyvitamin D, analogs and uses thereof
|
US20040043971A1
(en)
*
|
1995-04-03 |
2004-03-04 |
Bone Care International, Inc. |
Method of treating and preventing hyperparathyroidism with active vitamin D analogs
|
JPH11504631A
(ja)
*
|
1995-04-25 |
1999-04-27 |
バイカル インコーポレイテッド |
Dna/脂質複合体の単一バイアル製剤
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
US5739271A
(en)
*
|
1995-06-07 |
1998-04-14 |
Gen-Probe Incorporated |
Thiocationic lipids
|
US5994315A
(en)
*
|
1995-06-07 |
1999-11-30 |
East Carolina University |
Low adenosine agent, composition, kit and method for treatment of airway disease
|
US5756352A
(en)
*
|
1995-06-07 |
1998-05-26 |
Gen-Probe Incorporated |
Thiocationic lipid-nucleic acid conjugates
|
US5711964A
(en)
*
|
1995-06-07 |
1998-01-27 |
United States Of America |
Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
JPH11507815A
(ja)
|
1995-06-07 |
1999-07-13 |
ジンタ・インコーポレイテッド |
ホスホン酸基本カチオン性脂質
|
DE69634084T2
(de)
*
|
1995-06-07 |
2005-12-08 |
Inex Pharmaceuticals Corp. |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
US5705385A
(en)
*
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6251939B1
(en)
|
1995-06-07 |
2001-06-26 |
Promega Biosciences, Inc. |
Carbamate-based cationic lipids
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US5851548A
(en)
*
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
US6051429A
(en)
*
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
WO1996040961A1
(fr)
*
|
1995-06-07 |
1996-12-19 |
Life Technologies, Inc. |
Transfection par lipides cationiques amelioree par des peptides
|
US5869040A
(en)
*
|
1995-06-07 |
1999-02-09 |
Biogen, Inc |
Gene therapy methods and compositions
|
US5759519A
(en)
*
|
1995-06-07 |
1998-06-02 |
Gen-Probe Incorporated |
Method for the intracellular delivery of biomolecules using thiocationic lipids
|
CA2222586A1
(fr)
*
|
1995-06-07 |
1996-12-19 |
Gen-Probe Incorporated |
Lipides thiocationiques, preparations pharmaceutiques et leurs modes d'utilisation
|
DE19521412A1
(de)
*
|
1995-06-14 |
1996-12-19 |
Boehringer Mannheim Gmbh |
Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
|
US5931809A
(en)
*
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
US6339173B1
(en)
|
1996-07-22 |
2002-01-15 |
Promega Biosciences, Inc. |
Amide-based cationic lipids
|
WO1997003939A1
(fr)
*
|
1995-07-21 |
1997-02-06 |
Genta Incorporated |
Nouveaux lipides cationiques a base d'amides
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
NO953680D0
(no)
*
|
1995-09-18 |
1995-09-18 |
Hans Prydz |
Cellesyklusenzymer
|
US6120794A
(en)
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
AU7078396A
(en)
*
|
1995-09-27 |
1997-04-30 |
Regents Of The University Of California, The |
Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
|
US5869715A
(en)
*
|
1995-09-27 |
1999-02-09 |
The Reagents Of The University Of California |
Polyfunctional cationic cytofectins
|
US6086913A
(en)
*
|
1995-11-01 |
2000-07-11 |
University Of British Columbia |
Liposomal delivery of AAV vectors
|
WO1997019675A2
(fr)
*
|
1995-11-30 |
1997-06-05 |
Vical Incorporated |
Lipides cationiques complexes
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6126964A
(en)
*
|
1996-01-04 |
2000-10-03 |
Mirus Corporation |
Process of making a compound by forming a polymer from a template drug
|
AUPN741696A0
(en)
*
|
1996-01-05 |
1996-01-25 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids ii
|
US7002027B1
(en)
*
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US6392069B2
(en)
*
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
WO1997028817A1
(fr)
*
|
1996-02-09 |
1997-08-14 |
Cheng Pi Wan |
Administration de molecules actives biologiquement, facilitee par un ligand recepteur
|
US5783566A
(en)
*
|
1996-05-10 |
1998-07-21 |
California Institute Of Technology |
Method for increasing or decreasing transfection efficiency
|
AU2214597A
(en)
*
|
1996-03-18 |
1997-10-10 |
California Institute Of Technology |
Methods for increasing or decreasing transfection efficiency
|
US5994317A
(en)
*
|
1996-04-09 |
1999-11-30 |
Vical Incorporated |
Quaternary cytofectins
|
US5798250A
(en)
*
|
1996-04-15 |
1998-08-25 |
Icn Pharmaceuticals, Inc. |
Facilitating hepatitus virus infection in cell culture using a membrane stressor
|
CA2252617A1
(fr)
*
|
1996-05-01 |
1997-11-06 |
Imarx Pharmaceutical Corp. |
Procedes d'apport de composes dans une cellule
|
JP2000509404A
(ja)
*
|
1996-05-08 |
2000-07-25 |
ニカ ヘルス プロダクツ リミテッド |
遺伝物質の導入システムとしてのカチオン性ヴィロソーム
|
WO1997042819A1
(fr)
*
|
1996-05-13 |
1997-11-20 |
Alberto Haces |
Lipides cationiques destines a la transfection de molecules neutres ou chargees negativement a l'interieur de cellules vivantes
|
US5980935A
(en)
*
|
1996-05-15 |
1999-11-09 |
Kirpotin; Dmitri |
Cationic lipids and methods of use therefor
|
US8323963B2
(en)
*
|
1996-05-29 |
2012-12-04 |
University Of Southern California |
Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
|
US6274136B1
(en)
*
|
1996-05-29 |
2001-08-14 |
University Of Southern California |
Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
|
US5935936A
(en)
*
|
1996-06-03 |
1999-08-10 |
Genzyme Corporation |
Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US6093816A
(en)
*
|
1996-06-27 |
2000-07-25 |
Isis Pharmaceuticals, Inc. |
Cationic lipids
|
AU3514197A
(en)
*
|
1996-07-03 |
1998-01-21 |
Genetics Institute Inc. |
Protease fmh-1, an ice/ced-like protease
|
CA2261887C
(fr)
*
|
1996-07-23 |
2007-10-02 |
Oregon Health Sciences University |
Conjugues lipidiques polaires covalents associes a des composes biologiquement actifs utilisables dans les onguents
|
EP1254657B1
(fr)
*
|
1996-09-13 |
2008-05-21 |
Lipoxen Technologies Limited |
Liposomes
|
US7384923B2
(en)
*
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
KR20000048820A
(ko)
|
1996-10-01 |
2000-07-25 |
게론 코포레이션 |
텔로머라제 역전사 효소
|
US5861397A
(en)
*
|
1996-10-03 |
1999-01-19 |
Vical Incorporated |
Piperazine based cytofectins
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
FR2754828B1
(fr)
*
|
1996-10-23 |
1998-12-24 |
Univ Toulouse |
Structure membranaire artificielle, procede et polymere pour sa preparation, procede de preparation de ce polymere, particule et film comprenant cette structure
|
US6210707B1
(en)
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
PT956001E
(pt)
*
|
1996-11-12 |
2012-12-06 |
Univ California |
Preparação de formulações estáveis de complexos do tipo lípido-ácido nucleico para uma entrega eficiente in vivo
|
US5965441A
(en)
*
|
1996-11-13 |
1999-10-12 |
The General Hospital Coporation |
HSV/AAV hybrid amplicon vectors
|
WO1998024936A1
(fr)
*
|
1996-12-06 |
1998-06-11 |
The Regents Of The University Of California |
Complexes macromolecule/lipide et procedes de fabrication et d'utilisation
|
DE69732789T2
(de)
|
1996-12-06 |
2005-08-11 |
Aventis Pharmaceuticals Inc. |
Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
|
US7008776B1
(en)
*
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
US20020128240A1
(en)
*
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
US6527716B1
(en)
|
1997-12-30 |
2003-03-04 |
Altea Technologies, Inc. |
Microporation of tissue for delivery of bioactive agents
|
US20030129194A1
(en)
*
|
1997-02-13 |
2003-07-10 |
Bone Care International, Inc. |
Targeted therapeutic delivery of vitamin D compounds
|
US6929797B2
(en)
*
|
1997-02-13 |
2005-08-16 |
Bone Care International, Inc. |
Targeted therapeutic delivery of vitamin D compounds
|
FR2760193B1
(fr)
*
|
1997-02-28 |
1999-05-28 |
Transgene Sa |
Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
|
US5837283A
(en)
*
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US7112338B2
(en)
*
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5965542A
(en)
*
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
US5948653A
(en)
|
1997-03-21 |
1999-09-07 |
Pati; Sushma |
Sequence alterations using homologous recombination
|
US5925628A
(en)
*
|
1997-03-31 |
1999-07-20 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5958894A
(en)
*
|
1997-04-04 |
1999-09-28 |
Megabios Corporation |
Amphiphilic biguanide derivatives
|
US5912239A
(en)
*
|
1997-04-04 |
1999-06-15 |
Genzyme Corporation |
Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US6235310B1
(en)
|
1997-04-04 |
2001-05-22 |
Valentis, Inc. |
Methods of delivery using cationic lipids and helper lipids
|
FR2761912B1
(fr)
*
|
1997-04-14 |
1999-07-02 |
Capsulis |
Procede destine a faire adherer un produit sur une surface
|
CN1177934C
(zh)
*
|
1997-04-28 |
2004-12-01 |
阿文蒂斯药物股份有限公司 |
腺病毒介导的肿瘤内投送血管生成拮抗剂用于肿瘤的治疗
|
NZ500694A
(en)
*
|
1997-04-30 |
2001-09-28 |
Univ Minnesota |
Use of chimeric mutational vector (CMV), a macromolecule and a ligand for cell surface receptor adhesion molecule (clatherin) in gene therapy; the CMV vector derived from REC2 homologous pairing with Ustilago maydis
|
US5948925A
(en)
*
|
1997-05-06 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
|
US5952516A
(en)
*
|
1997-05-08 |
1999-09-14 |
Genzyme Corporation |
Cationic amphiphiles containing multiplesteroid lipophilic groups
|
US5942634A
(en)
*
|
1997-05-09 |
1999-08-24 |
Genzyme Corporation |
Cationic amphiphiles for cell transfections
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
JP4656675B2
(ja)
*
|
1997-05-14 |
2011-03-23 |
ユニバーシティー オブ ブリティッシュ コロンビア |
脂質小胞への荷電した治療剤の高率封入
|
US20030104044A1
(en)
*
|
1997-05-14 |
2003-06-05 |
Semple Sean C. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
EP1007099A4
(fr)
|
1997-07-11 |
2004-11-24 |
Univ Brandeis |
Procede pour induire l'apoptose par la reduction du taux de thiamine
|
US20090239940A1
(en)
*
|
1997-07-22 |
2009-09-24 |
Del Monte Federica |
Treating heart failure and ventricular arrhythmias
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
US6300127B1
(en)
|
1997-07-30 |
2001-10-09 |
Emory University |
Bone mineralization proteins, DNA, vectors, expression systems
|
ATE376062T1
(de)
|
1997-08-04 |
2007-11-15 |
Cell Genesys Inc |
Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
|
JP2001512830A
(ja)
|
1997-08-08 |
2001-08-28 |
ニューバイオティックス インコーポレイテッド |
生物療法耐性および化学療法耐性を克服するための方法および組成物
|
US6281371B1
(en)
|
1997-08-13 |
2001-08-28 |
Biontex Laboratories Gmbh |
Lipopolyamines, and the preparation and use thereof
|
US6818627B1
(en)
|
1997-08-14 |
2004-11-16 |
The Trustees Of The University Of Pennsylvania |
Functional fragments of HIV-1 Vpr protein and methods of using the same
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US6884842B2
(en)
|
1997-10-14 |
2005-04-26 |
Alnis Biosciences, Inc. |
Molecular compounds having complementary surfaces to targets
|
US6875606B1
(en)
|
1997-10-23 |
2005-04-05 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Human α-7 nicotinic receptor promoter
|
US5998482A
(en)
*
|
1997-11-10 |
1999-12-07 |
David; Sunil A. |
Use of synthetic polycationic amphiphilic substances with fatty acid or hydrocarbon substituents as anti-sepsis agents
|
JP2001523480A
(ja)
|
1997-11-20 |
2001-11-27 |
バイカル インコーポレイテッド |
サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
|
ATE293994T1
(de)
*
|
1997-12-01 |
2005-05-15 |
Fang Fang |
Multivalente rekombinante antikörper zur behandlung von hrv infektionen
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
FR2772047B1
(fr)
*
|
1997-12-05 |
2004-04-09 |
Ct Nat D Etudes Veterinaires E |
Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
AU2324999A
(en)
*
|
1998-01-16 |
1999-08-02 |
California Pacific Medical Center Research Institute |
Methods and compositions for gene delivery
|
ES2172303T3
(es)
|
1998-01-23 |
2002-09-16 |
Newbiotics Inc |
Agentes terapeuticos obtenidos por catalisis enzimatica.
|
US7462605B2
(en)
*
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
DE69943022D1
(de)
|
1998-03-19 |
2011-01-20 |
Human Genome Sciences Rockville |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
US6043390A
(en)
*
|
1998-04-03 |
2000-03-28 |
The Regents Of The University Of California |
Pentaerythritol lipid derivatives and nucleic-acid complexes
|
US6271209B1
(en)
*
|
1998-04-03 |
2001-08-07 |
Valentis, Inc. |
Cationic lipid formulation delivering nucleic acid to peritoneal tumors
|
AU754434B2
(en)
|
1998-05-06 |
2002-11-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Novel inhibitors of NF-kappaB activation
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
DK1082415T3
(da)
*
|
1998-05-29 |
2011-06-14 |
Scripps Research Inst |
Anvendelige fremgangsmåder til modulation af angioge-nese ved anvendelse af tyrosin kinase SRC
|
US6200598B1
(en)
*
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6726925B1
(en)
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
US20040077603A1
(en)
*
|
1998-08-28 |
2004-04-22 |
Wilhelm Stoffel |
Synthetic tear fluid
|
ES2394458T3
(es)
*
|
1998-09-09 |
2013-01-31 |
Genzyme Corporation |
Metilación de vectores plasmídicos
|
US6135976A
(en)
|
1998-09-25 |
2000-10-24 |
Ekos Corporation |
Method, device and kit for performing gene therapy
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
ATE383331T1
(de)
|
1998-11-12 |
2008-01-15 |
Invitrogen Corp |
Transportreagentien
|
WO2000030444A1
(fr)
|
1998-11-25 |
2000-06-02 |
Vanderbilt University |
Liposomes cationiques pour transfert genique
|
AU1828100A
(en)
|
1998-11-25 |
2000-06-13 |
Gene Therapy Systems, Inc. |
Amphiphilic polyamine compounds
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US20020032164A1
(en)
|
1998-12-30 |
2002-03-14 |
Dale Roderic M. K. |
Antimicrobial compounds and methods for their use
|
US7868162B2
(en)
|
1998-12-30 |
2011-01-11 |
Lakewood-Amedex, Inc. |
Antimicrobial and antiviral compounds and methods for their use
|
US6627215B1
(en)
|
1998-12-30 |
2003-09-30 |
Oligos Etc. Inc. |
Devices for improved wound management
|
US6441156B1
(en)
*
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
US6570003B1
(en)
*
|
2001-01-09 |
2003-05-27 |
Lexion Genetics Incorporated |
Human 7TM proteins and polynucleotides encoding the same
|
EP1147204A1
(fr)
*
|
1999-01-28 |
2001-10-24 |
Medical College Of Georgia Research Institute, Inc. |
Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
|
EP1159000B1
(fr)
|
1999-02-25 |
2002-09-25 |
Pogge von Strandmann, Elke |
Agent pour traiter des troubles de la pigmentation
|
KR20070053815A
(ko)
|
1999-03-03 |
2007-05-25 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
백신 및 유전자요법 조성물 및 이들의 제조 및 사용방법
|
US7393548B2
(en)
*
|
1999-03-22 |
2008-07-01 |
J.P. M.E.D. Ltd. |
Nano oil in glycerin emulsion
|
WO2000056914A1
(fr)
|
1999-03-24 |
2000-09-28 |
Gene Therapy Systems, Inc. |
Procede de production de fragments d'adn transcriptionnellement actifs
|
DK1459766T3
(da)
|
1999-03-26 |
2008-10-13 |
Vical Inc |
Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
|
US6379698B1
(en)
*
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6696424B1
(en)
|
1999-05-28 |
2004-02-24 |
Vical Incorporated |
Cytofectin dimers and methods of use thereof
|
DE60016205T2
(de)
*
|
1999-05-28 |
2005-12-01 |
Vical, Inc., San Diego |
Cytofectin-dimere und verfahren zu ihrer anwendung
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6943152B1
(en)
|
1999-06-10 |
2005-09-13 |
Merial |
DNA vaccine-PCV
|
US20010048940A1
(en)
*
|
1999-06-18 |
2001-12-06 |
Jennifer D. Tousignant |
Cationic amphiphile micellar complexes
|
FR2797402B1
(fr)
|
1999-07-15 |
2004-03-12 |
Biomerieux Stelhys |
Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
|
US6683061B1
(en)
|
1999-07-22 |
2004-01-27 |
Newbiotics, Inc. |
Enzyme catalyzed therapeutic activation
|
WO2001007088A2
(fr)
|
1999-07-22 |
2001-02-01 |
Newbiotics, Inc. |
Procedes pour traiter les tumeurs resistantes aux therapies
|
US20030078499A1
(en)
*
|
1999-08-12 |
2003-04-24 |
Eppstein Jonathan A. |
Microporation of tissue for delivery of bioactive agents
|
US20050249794A1
(en)
*
|
1999-08-27 |
2005-11-10 |
Semple Sean C |
Compositions for stimulating cytokine secretion and inducing an immune response
|
AUPQ259399A0
(en)
*
|
1999-09-01 |
1999-09-23 |
Lustre Investments Pte Ltd |
Therapeutic agents
|
US20030166902A1
(en)
*
|
2001-02-20 |
2003-09-04 |
Yi Hu |
Novel human protease and polynucleotides encoding the same
|
US20080003673A1
(en)
*
|
1999-09-02 |
2008-01-03 |
Alejandro Abuin |
Novel human proteases and polynucleotides encoding the same
|
US6448388B1
(en)
|
2000-08-16 |
2002-09-10 |
Lexicon Genetics Incorporated |
Human proteases and polynucleotides encoding the same
|
US20030050464A1
(en)
*
|
2000-07-28 |
2003-03-13 |
Yi Hu |
Novel human proteases and polynucleotides encoding the same
|
US7374933B2
(en)
*
|
2000-04-12 |
2008-05-20 |
Lexicon Pharmaceuticals, Inc. |
Human metalloprotease and polynucleotides encoding the same
|
US20010034437A1
(en)
*
|
2000-01-06 |
2001-10-25 |
Walke D. Wade |
Novel human proteases and polynucleotides encoding the same
|
US6716614B1
(en)
|
1999-09-02 |
2004-04-06 |
Lexicon Genetics Incorporated |
Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof
|
US20050153323A1
(en)
*
|
2000-07-28 |
2005-07-14 |
Yi Hu |
Novel human proteases and polynucleotides encoding the same
|
MXPA02002579A
(es)
*
|
1999-09-09 |
2003-10-14 |
Univ California |
Entrega de liposomas cationicas de taxanos a vasos sanguineos angiogenicos.
|
US6867291B1
(en)
*
|
2000-09-15 |
2005-03-15 |
Lexicon Genetics Incorporated |
Human hemicentin proteins and polynucleotides encoding the same
|
US20020107382A1
(en)
*
|
2000-09-27 |
2002-08-08 |
Friddle Carl Johan |
Novel human protease inhibitor proteins and polynucleotides encoding the same
|
US6790660B1
(en)
|
2001-09-18 |
2004-09-14 |
Lexicon Genetics Incorporated |
Human kielin-like proteins and polynucleotides encoding the same
|
US6579710B2
(en)
*
|
2000-12-12 |
2003-06-17 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US6797510B1
(en)
*
|
2001-05-24 |
2004-09-28 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US6734010B2
(en)
*
|
2001-05-09 |
2004-05-11 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US6541252B1
(en)
|
2000-05-19 |
2003-04-01 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US20080050809A1
(en)
*
|
1999-09-28 |
2008-02-28 |
Alejandro Abuin |
Novel human kinases and polynucleotides encoding the same
|
US6720173B1
(en)
|
1999-11-08 |
2004-04-13 |
Lexicon Genetics Incorporated |
Human kinase protein and polynucleotides encoding the same
|
US6511840B1
(en)
|
2000-06-15 |
2003-01-28 |
Lexicon Genetics Incorporated |
Human kinase proteins and polynucleotides encoding the same
|
US6841377B1
(en)
*
|
2001-06-13 |
2005-01-11 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US6586230B1
(en)
|
2000-10-27 |
2003-07-01 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
US20080213878A1
(en)
*
|
1999-10-19 |
2008-09-04 |
Gregory Donoho |
Novel human membrane proteins and polynucleotides encoding the same
|
US6750054B2
(en)
|
2000-05-18 |
2004-06-15 |
Lexicon Genetics Incorporated |
Human semaphorin homologs and polynucleotides encoding the same
|
EP1242588A2
(fr)
|
1999-11-12 |
2002-09-25 |
Lexicon Genetics Incorporated |
Nouvelles proteases humaines et polynucleotides les codant
|
AU1920601A
(en)
*
|
1999-11-19 |
2001-05-30 |
Lexicon Genetics Incorporated |
Novel human secreted proteins and polynucleotides encoding the same
|
ES2170622B1
(es)
*
|
1999-12-03 |
2004-05-16 |
Consejo Superior De Investigaciones Cientificas |
Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
|
EP1244694A2
(fr)
*
|
1999-12-07 |
2002-10-02 |
Lexicon Genetics Incorporated |
Nouvelles proteines membranaires humaines et polynucleotides codant pour ces proteines
|
EP1240187A2
(fr)
|
1999-12-07 |
2002-09-18 |
Lexicon Genetics Incorporated |
Nouvelles proteines de kinase de l'homme et polynucleotides codant ces dernieres
|
US6692947B2
(en)
*
|
1999-12-13 |
2004-02-17 |
Lexicon Genetics Incorporated |
Human transferase proteins and polynucleotides encoding the same
|
US20030008813A1
(en)
*
|
1999-12-17 |
2003-01-09 |
Felgner Philip L. |
Intracellular protein delivery compositions and methods of use
|
WO2001046407A1
(fr)
*
|
1999-12-22 |
2001-06-28 |
Lexicon Genetics Incorporated |
Polynucleotides codant pour des homologues de proteases humaines
|
EP1250427A2
(fr)
*
|
1999-12-22 |
2002-10-23 |
Lexicon Genetics Incorporated |
Proteines membranaires ayant une homologie avec cd20 et les recepteurs pour ige et les polynucleotides codant pour ceux-ci
|
FR2802925B1
(fr)
*
|
1999-12-23 |
2002-03-22 |
Commissariat Energie Atomique |
Amphiphiles cationiques, leurs applications et leur procede de synthese
|
WO2001048164A2
(fr)
*
|
1999-12-27 |
2001-07-05 |
The Regents Of The University Of California |
Therapie genique destinee a une insuffisance cardiaque congestive
|
CN1433478A
(zh)
*
|
1999-12-30 |
2003-07-30 |
诺瓦提斯公司 |
用于基因治疗的新的胶体合成载体
|
AU784540B2
(en)
*
|
2000-01-18 |
2006-04-27 |
Lexicon Pharmaceuticals, Inc. |
Novel human kinase protein and polynucleotides encoding the same
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20040002472A1
(en)
*
|
2000-01-21 |
2004-01-01 |
Audonnet Jean-Christophe Francis |
Vaccination or immunization using a prime-boost regimen
|
US7078388B2
(en)
*
|
2000-01-21 |
2006-07-18 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
US6852705B2
(en)
|
2000-01-21 |
2005-02-08 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
JP2004500084A
(ja)
*
|
2000-01-26 |
2004-01-08 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトニューレキシン様タンパク質及び該タンパク質をコードするポリヌクレオチド
|
JP2003520607A
(ja)
*
|
2000-01-28 |
2003-07-08 |
レキシコン・ジェネティクス・インコーポレーテッド |
ヒト膜タンパクおよびそれをコードするポリヌクレオチド
|
EP1301600A2
(fr)
*
|
2000-01-28 |
2003-04-16 |
Lexicon Genetics Incorporated |
Enzymes humaines et polynucleotides les codant
|
AU3665901A
(en)
*
|
2000-02-04 |
2001-08-14 |
Lexicon Genetics Incorporated |
Novel human enzymes and polynucleotides encoding the same
|
EP1257579B1
(fr)
*
|
2000-02-04 |
2009-08-05 |
Lexicon Pharmaceuticals, Inc. |
Nouvelles proteines membranaires humaines et les polynucleotides les codant
|
CA2398590C
(fr)
|
2000-02-08 |
2012-08-28 |
Sangamo Biosciences, Inc. |
Cellules destinees a la decouverte de medicaments
|
EP1255843A1
(fr)
|
2000-02-11 |
2002-11-13 |
Lexicon Genetics Incorporated |
Proteases humaines et polynucleotides codant pour elles
|
CN1280103C
(zh)
|
2000-02-16 |
2006-10-18 |
精工爱普生株式会社 |
喷墨打印机用连接组件及喷墨打印机
|
AU2001238503A1
(en)
|
2000-02-17 |
2001-08-27 |
Lexicon Genetics Incorporated |
Novel human thrombospondin repeat proteins and polynucleotides encoding the same
|
AU2001245370A1
(en)
|
2000-02-29 |
2001-09-12 |
Lexicon Genetics Incorporated |
Novel human transferase proteins and polynucleotides encoding the same
|
JP2003531582A
(ja)
*
|
2000-02-29 |
2003-10-28 |
レキシコン・ジェネティクス・インコーポレーテッド |
ヒトトランスポータータンパクおよびそれをコードするポリヌクレオチド
|
AU2001247283A1
(en)
*
|
2000-03-06 |
2001-09-17 |
Lexicon Genetics Incorporated |
Human transporter proteins and polynucleotides encoding the same
|
WO2001068869A2
(fr)
|
2000-03-10 |
2001-09-20 |
Lexicon Genetics Incorporated |
Nouveaux recepteurs kinases couples a la proteine g et polynucleotides les codant
|
WO2001068131A1
(fr)
|
2000-03-13 |
2001-09-20 |
Cornell Research Foundation, Inc. |
Inhibition de la migration des leucocytes et d'une inflammation par perturbation de cd99/hec2
|
AU2001247395B2
(en)
*
|
2000-03-13 |
2006-08-31 |
Lexicon Pharmaceuticals, Inc. |
Novel human phospholipases and polynucleotides encoding the same
|
NZ521199A
(en)
|
2000-03-13 |
2004-11-26 |
Engene Inc |
Mucosal cells producing nutrient-regulated protein expressed by a transgene comprising an expression control element linked with a nucleic acid encoding protein, for treating diabetes
|
AU2001245871B2
(en)
*
|
2000-03-20 |
2006-06-01 |
Lexicon Pharmaceuticals, Inc. |
Novel human secreted proteins and polynucleotides encoding the same
|
US20040102388A1
(en)
*
|
2000-03-22 |
2004-05-27 |
High Katherine A. |
Modified blood clotting factors and methods of use
|
US20040033600A1
(en)
|
2001-03-21 |
2004-02-19 |
Palli Subba Reddy |
Ecdysone receptor-based inducible gene expression system
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
JP2004505610A
(ja)
*
|
2000-04-03 |
2004-02-26 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトイオンチャンネルタンパク質およびそれをコードするポリヌクレオチド
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
JP2003531149A
(ja)
|
2000-04-13 |
2003-10-21 |
ザ・ロツクフエラー・ユニバーシテイ |
抗体由来の免疫応答の増強
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
EP1278551A2
(fr)
*
|
2000-04-21 |
2003-01-29 |
Vical Incorporated |
Compositions pour l'administration i in vivo /i d'agents therapeutiques derives de polynucleotides et methodes associees
|
AU2001257195B2
(en)
|
2000-04-25 |
2006-10-05 |
Lexicon Pharmaceuticals, Inc. |
Novel human kinase proteins and polynucleotides encoding the same
|
AU2001263107A1
(en)
*
|
2000-05-12 |
2001-11-26 |
Lexicon Genetics Incorporated |
Novel human lipocalin homologs and polynucleotides encoding the same
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
WO2001090179A2
(fr)
*
|
2000-05-23 |
2001-11-29 |
Lexicon Genetics Incorporated |
Proteines ressemblant a la thrombospondine humaine et polynucleotides les codant
|
US6790667B1
(en)
|
2000-05-30 |
2004-09-14 |
Lexicon Genetics Incorporated |
Human mitochondrial proteins and polynucleotides encoding the same
|
DK2298799T3
(en)
|
2000-06-05 |
2018-02-19 |
Brigham & Womens Hospital Inc |
Gene encoding a human multi-resistance β-glycoprotein homolog on chromosome 7p15-21, and uses thereof
|
AU2001275337A1
(en)
*
|
2000-06-07 |
2001-12-17 |
Lexicon Genetics Incorporated |
Novel human transporter proteins and polynucleotides encoding the same
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
AU2001264317A1
(en)
*
|
2000-06-20 |
2002-01-02 |
Koken Co., Ltd. |
Preparations for oligonucleotide transfer
|
WO2002000720A2
(fr)
*
|
2000-06-27 |
2002-01-03 |
Lexicon Genetics Incorporated |
Nouveaux recepteurs gaba humains et polynucleotides les codant
|
EP2070911A2
(fr)
*
|
2000-07-18 |
2009-06-17 |
Bone Care International, Inc. |
1Alpha-hydroxy vitamine D stabilisée
|
AU2002224553A1
(en)
*
|
2000-07-21 |
2002-02-05 |
Incyte Genomics, Inc. |
Human proteases
|
US6887685B1
(en)
*
|
2000-07-25 |
2005-05-03 |
Lexicon Genetics Incorporated |
Human thymosin protein and polynucleotides encoding the same
|
JP2004505113A
(ja)
*
|
2000-07-27 |
2004-02-19 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア |
単純疱疹ウイルス糖蛋白質dを用いた組成物及びそれを用いて免疫応答を抑制する方法
|
US20020076780A1
(en)
*
|
2000-08-16 |
2002-06-20 |
Turner C. Alexander |
Novel human ion channel proteins and polynucleotides encoding the same
|
AU2001286792A1
(en)
*
|
2000-08-22 |
2002-03-04 |
Lexicon Genetics Incorporated |
Novel human 7TM proteins and polynucleotides encoding the same
|
JP2004531201A
(ja)
*
|
2000-08-22 |
2004-10-14 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトプロテアーゼ及び該プロテアーゼをコードするポリヌクレオチド
|
CA2420325A1
(fr)
|
2000-08-25 |
2002-02-28 |
Basf Plant Science Gmbh |
Polynucleotides vegetaux codant de nouvelles proteases prenyle
|
AU2001285326A1
(en)
*
|
2000-08-31 |
2002-03-13 |
Lexicon Genetics Incorporated |
Human kinase proteins and polynucleotides encoding the same
|
WO2002020753A2
(fr)
*
|
2000-09-01 |
2002-03-14 |
Lexicon Genetics Incorporated |
Nouvelle proteine transporteur gaba humaine et polynucleotides codant pour cette derniere
|
JP2004509641A
(ja)
*
|
2000-09-27 |
2004-04-02 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトイオン交換タンパク質およびそれをコードするポリヌクレオチド
|
US6777232B1
(en)
*
|
2000-10-02 |
2004-08-17 |
Lexicon Genetics Incorporated |
Human membrane proteins and polynucleotides encoding the same
|
US8105825B2
(en)
|
2000-10-03 |
2012-01-31 |
Intrexon Corporation |
Multiple inducible gene regulation system
|
US20050059031A1
(en)
|
2000-10-06 |
2005-03-17 |
Quantum Dot Corporation |
Method for enhancing transport of semiconductor nanocrystals across biological membranes
|
WO2002031129A2
(fr)
|
2000-10-12 |
2002-04-18 |
Lexicon Genetics Incorporated |
Nouvelles kinases humaines et polynucleotides codant pour ces dernieres
|
US7001763B1
(en)
|
2000-10-17 |
2006-02-21 |
Lexicon Genetics Incorporated |
Human semaphorin proteins and polynucleotides encoding the same
|
US6831059B2
(en)
|
2000-10-20 |
2004-12-14 |
Allergan, Inc. |
Compositions and methods for treating gonadotrophin related illnesses
|
EP1624062A3
(fr)
*
|
2000-10-27 |
2006-02-22 |
Lexicon Genetics Incorporated |
Récepteur 7tm humain et acides nucléiques le codant
|
US20020086849A1
(en)
*
|
2000-10-27 |
2002-07-04 |
Gulilat Gebeyehu |
Method for introducing antisense oligonucleotides into eucaryotic cells
|
EP1330524A2
(fr)
*
|
2000-10-30 |
2003-07-30 |
Lexicon Genetics Incorporated |
Nouvelles proteines humaines 7tm et polynucleotides codant pour ces proteines
|
US7060442B2
(en)
*
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
CA2427828A1
(fr)
*
|
2000-11-01 |
2002-05-10 |
Lexicon Genetics Incorporated |
Nouvelles proteases humaines et polynucleotides codant pour lesdites proteases
|
JP2004535154A
(ja)
*
|
2000-11-15 |
2004-11-25 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒト分泌タンパク質およびそれをコードするポリヌクレオチド
|
WO2002042438A2
(fr)
*
|
2000-11-20 |
2002-05-30 |
Lexicon Genetics Incorporated |
Nouvelles kinases humaines et polynucleotides codant pour celles-ci
|
WO2002044396A1
(fr)
*
|
2000-11-29 |
2002-06-06 |
Pci Biotech As |
Internalisation photochimique pour introduire des molecules dans le cytosol
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
JP2004517622A
(ja)
*
|
2000-12-11 |
2004-06-17 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトキナーゼ及び該キナーゼをコードするポリヌクレオチド
|
US6583269B1
(en)
|
2000-12-18 |
2003-06-24 |
Lexicon Genetics Incorporated |
Human protease inhibitor and polynucleotides encoding the same
|
US6852844B1
(en)
|
2000-12-20 |
2005-02-08 |
Lexicon Genetics Incorporated |
Human protocadherin proteins and polynucleotides encoding the same
|
JP2005502307A
(ja)
*
|
2000-12-20 |
2005-01-27 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトイオンチャンネルタンパクおよびそれをコードするポリヌクレオチド
|
AU2002246858A1
(en)
*
|
2000-12-27 |
2002-08-06 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
DE10064870B4
(de)
*
|
2000-12-27 |
2004-10-07 |
G.O.T. Gesellschaft Zur Therapieoptimierung Und Targeting Entwicklungs Mbh |
Schwefelhaltige Amphiphile für den Transfer von biologisch aktiven Molekülen in Zellen
|
IL155726A0
(en)
|
2000-12-28 |
2003-11-23 |
Wyeth Corp |
Recombinant protective protein from streptococcus pneumoniae
|
US20020115844A1
(en)
*
|
2001-01-05 |
2002-08-22 |
Yu Xuanchuan Sean |
Novel human lipase and polynucleotides encoding the same
|
AU2002236717A1
(en)
*
|
2001-01-08 |
2002-07-16 |
Lexicon Genetics Incorporated |
Human protease and polynucleotides encoding the same
|
WO2002056832A2
(fr)
*
|
2001-01-19 |
2002-07-25 |
Newbiotics, Inc. |
Procedes relatifs au traitement des maladies auto-immunes et inflammatoires
|
CA2434896A1
(fr)
*
|
2001-01-23 |
2002-08-01 |
Lexicon Genetics Incorporated |
Nouvelles kinases humaines et polynucleotides codant pour celles-ci
|
CA2434897A1
(fr)
*
|
2001-01-24 |
2002-08-01 |
Lexicon Genetics Incorporated |
Lipase humaine et polynucleotides codant pour cette lipase
|
CA2369944A1
(fr)
*
|
2001-01-31 |
2002-07-31 |
Nucleonics Inc. |
Utilisation de l'inhibition genetique post-transcriptionnelle pour identifier les sequences d'acides nucleiques qui modulent la fonction d'une cellule
|
WO2002063002A2
(fr)
*
|
2001-02-02 |
2002-08-15 |
Lexicon Genetics Incorporated |
Nouvelle proteine transporteuse humaine et polynucleotides la codant
|
DK1534738T3
(da)
|
2001-02-20 |
2012-10-01 |
Intrexon Corp |
Nye substitutionsmutantreceptorer og anvendelse heraf i et inducérbart genekpressionssystem på basis af en nuklear receptor
|
WO2002066614A2
(fr)
*
|
2001-02-20 |
2002-08-29 |
Rheogene Holdings, Inc. |
Recepteurs x de retinoides chimeriques et utilisations de ceux-ci dans un nouveau systeme d'expression de gene inductible fonde sur un recepteur d'ecdysone
|
EP1373470B1
(fr)
|
2001-02-20 |
2013-04-24 |
Intrexon Corporation |
Nouveaux recepteurs de mutants de substitution et utilisation de ceux-ci dans un systeme d'expression genique inductible a base de recepteurs nucleaires
|
ES2385598T3
(es)
|
2001-02-20 |
2012-07-27 |
Intrexon Corporation |
Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
|
ATE448793T1
(de)
|
2001-03-02 |
2009-12-15 |
Univ Rockefeller |
Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
|
JP3929250B2
(ja)
*
|
2001-03-08 |
2007-06-13 |
株式会社ルネサステクノロジ |
半導体装置
|
WO2002072774A2
(fr)
*
|
2001-03-12 |
2002-09-19 |
Lexicon Genetics Incorporated |
Nouvelles proteines transporteuses humaines et polynucleotides codant pour ces proteines
|
US7252990B2
(en)
*
|
2001-03-12 |
2007-08-07 |
Lexicon Genetics Incorporated |
Human dectin proteins and polynucleotides encoding the same
|
JP2004535781A
(ja)
*
|
2001-03-12 |
2004-12-02 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトefgファミリータンパクおよびそれをコードするポリヌクレオチド
|
AU2002254174A1
(en)
*
|
2001-03-13 |
2002-09-24 |
Vical Incorporated |
Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
|
US6994995B1
(en)
*
|
2001-03-16 |
2006-02-07 |
Lexicon Genetics Incorporated |
Human synaptotagmin and polynucleotides encoding the same
|
WO2002074932A2
(fr)
|
2001-03-20 |
2002-09-26 |
Lexicon Genetics Incorporated |
Nouvelle kinase humaine et polynucleotides codant celle-ci
|
US6613534B2
(en)
|
2001-03-20 |
2003-09-02 |
Wake Forest University Health Sciences |
MAP-2 as a determinant of metastatic potential
|
US6936469B2
(en)
*
|
2001-03-22 |
2005-08-30 |
Chromos Molecular Systems Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US7294511B2
(en)
|
2001-03-22 |
2007-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US20030186390A1
(en)
*
|
2001-03-22 |
2003-10-02 |
De Jong Gary |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US20030096414A1
(en)
*
|
2001-03-27 |
2003-05-22 |
Invitrogen Corporation |
Culture medium for cell growth and transfection
|
US20040028651A1
(en)
*
|
2001-03-29 |
2004-02-12 |
Karrupiah Muthumani |
Composition and methods of using hiv vpr
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
EP1383879A4
(fr)
*
|
2001-04-06 |
2005-05-11 |
Lexicon Genetics Inc |
Kinases humaines et polynucleotides codant pour celles-ci
|
EP1390075B1
(fr)
*
|
2001-04-06 |
2012-01-18 |
The University of Chicago |
Induction chimiotherapeutique de l'activite du promoteur egr-1 dans la therapie genique
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
EP1383880A1
(fr)
*
|
2001-04-06 |
2004-01-28 |
Lexicon Genetics Incorporated |
Nouvelle kinase humaine et polynucleotides codant ces dernieres
|
US6644173B2
(en)
*
|
2001-04-11 |
2003-11-11 |
Keuring, Incorporated |
Beverage filter cartridge holder
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
AU2002257142B2
(en)
|
2001-04-13 |
2008-09-04 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
CA2443493A1
(fr)
*
|
2001-04-13 |
2002-10-24 |
Wyeth |
Proteines de surface de streptococcus pyogenes
|
US6607895B2
(en)
|
2001-04-16 |
2003-08-19 |
Lexicon Genetics Incorporated |
Human adenylsuccinate synthetase and polynucleotides encoding the same
|
US20020165175A1
(en)
*
|
2001-04-17 |
2002-11-07 |
Xiaowu Liang |
Fast and enzymeless cloning of nucleic acid fragments
|
WO2002087541A1
(fr)
*
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Formulations a base de lipides pour transfert genique
|
WO2002088313A2
(fr)
*
|
2001-04-30 |
2002-11-07 |
Lexicon Genetics Incorporated |
Nouveaux transporteurs nucleaires humains et polynucleotides codant ceux-ci
|
WO2002088318A2
(fr)
*
|
2001-04-30 |
2002-11-07 |
Targeted Genetics Corporation |
Complexes d'administration de medicaments contenant des lipides et leurs methodes de production
|
WO2002097095A1
(fr)
*
|
2001-05-25 |
2002-12-05 |
Lexicon Genetics Incorporated |
Nouvelles proteines transporteuses humaines et polynucleotides les codant
|
CA2448347C
(fr)
|
2001-05-29 |
2010-09-21 |
Lexicon Genetics Incorporated |
Nouvelles hydroxylases humaines et polynucleotides codant celles-ci
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
JP2004531268A
(ja)
*
|
2001-06-14 |
2004-10-14 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトトランスポータータンパクおよびそれをコードするポリヌクレオチド
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
DK2000545T3
(da)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
|
DE60232149D1
(de)
*
|
2001-06-20 |
2009-06-10 |
Dainippon Sumitomo Pharma Co |
Verfahren zur förderung des nukleinsäuretransfers
|
AU2002315393A1
(en)
|
2001-06-21 |
2003-01-08 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
CA2447249A1
(fr)
|
2001-06-22 |
2003-01-03 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Protection contre l'hepatite a mediation abin
|
CA2452088A1
(fr)
*
|
2001-06-26 |
2003-01-03 |
Elka Touitou |
Compositions et methodes d'administration intracellulaire
|
WO2003004609A2
(fr)
*
|
2001-07-03 |
2003-01-16 |
Lexicon Genetics Incorporated |
Nouvelles proteines humaines de type kieline et polynucleotides encodant ces dernieres
|
US20030207834A1
(en)
|
2001-07-10 |
2003-11-06 |
Dale Roderic M.K. |
Oligonucleotide-containing pharmacological compositions and their use
|
EP1578917A4
(fr)
|
2001-07-19 |
2008-01-23 |
Perlan Therapeutics Inc |
Proteines multimeres et methodes de production et d'utilisation de ces proteines
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US20040002468A1
(en)
*
|
2001-08-08 |
2004-01-01 |
Genzyme Corporation |
Methods of treating diabetes and other blood sugar disorders
|
US20040143104A1
(en)
*
|
2001-08-08 |
2004-07-22 |
Wadsworth Samuel C. |
Methods of treating diabetes and other blood sugar disorders
|
CA2457298A1
(fr)
*
|
2001-08-14 |
2003-02-27 |
Lexicon Genetics Incorporated |
Nouvelles proteines collagenes humaines et polynucleotides les codant
|
NZ573740A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184
|
WO2003027247A2
(fr)
|
2001-09-24 |
2003-04-03 |
Sangamo Biosciences, Inc. |
Modulation de cellules souches au moyen de proteines a doigts de zinc (zfp)
|
DE10244149A1
(de)
*
|
2001-09-25 |
2003-04-30 |
Werner Keber |
Verfahren und Einrichtung zum Verhindern einer unzulässigen Flugannäherung von Flugzeugen an zu schützende Bodenobjeke
|
JP2005532781A
(ja)
*
|
2001-09-26 |
2005-11-04 |
レオジーン・ホールディングス,インコーポレーテッド |
ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用
|
US7919269B2
(en)
|
2001-09-26 |
2011-04-05 |
Intrexon Corporation |
Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
JP2005523879A
(ja)
*
|
2001-10-05 |
2005-08-11 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
Sirs/sepsisを治療及び予防するための組成物及び方法
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
ATE516364T1
(de)
|
2001-10-09 |
2011-07-15 |
Isis Pharmaceuticals Inc |
Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
JP2005527639A
(ja)
|
2001-11-02 |
2005-09-15 |
インサート セラピューティクス インコーポレイテッド |
Rna干渉の治療的利用のための方法及び組成物
|
AU2002348163A1
(en)
*
|
2001-11-02 |
2003-05-19 |
Intradigm Corporation |
Therapeutic methods for nucleic acid delivery vehicles
|
US7488313B2
(en)
*
|
2001-11-29 |
2009-02-10 |
Boston Scientific Scimed, Inc. |
Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
WO2003052095A2
(fr)
*
|
2001-12-14 |
2003-06-26 |
Transgene S.A. |
Utilisation d'un lysolipide destine a la preparation d'une composition pour la transfection d'un polynucleotide dans une cellule
|
PT1456377T
(pt)
*
|
2001-12-20 |
2019-09-10 |
Merck Sharp & Dohme |
Composições de syn3 e processos
|
CA2471363C
(fr)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Proteines hybrides d'albumine
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003057728A1
(fr)
|
2002-01-10 |
2003-07-17 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Nouveau variant a epissage du myd88 et utilisations correspondantes
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
EP2221377B2
(fr)
|
2002-02-01 |
2017-05-17 |
Life Technologies Corporation |
Oligonucletides double brin
|
WO2003070905A2
(fr)
*
|
2002-02-15 |
2003-08-28 |
Zycos, Inc. |
Procedes d'electroporation pour introduire des agents bioactifs dans des cellules
|
DE10207177A1
(de)
*
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Fakultativ kationische Lipide
|
CA2477979A1
(fr)
*
|
2002-03-05 |
2003-09-18 |
Transave, Inc. |
Systeme d'inhalation pour le traitement d'infections intracellulaires
|
WO2003077970A2
(fr)
*
|
2002-03-11 |
2003-09-25 |
Altea Therapeutics Corporation |
Dispositif transdermique a actionneur integre, procedes de fabrication et d'utilisation de celui-ci
|
US9918665B2
(en)
|
2002-03-11 |
2018-03-20 |
Nitto Denko Corporation |
Transdermal porator and patch system and method for using same
|
US8116860B2
(en)
*
|
2002-03-11 |
2012-02-14 |
Altea Therapeutics Corporation |
Transdermal porator and patch system and method for using same
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
US7519418B2
(en)
*
|
2002-04-30 |
2009-04-14 |
Boston Scientific Scimed, Inc. |
Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
|
AU2003221584A1
(en)
*
|
2002-05-01 |
2003-11-17 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
EP1549352A4
(fr)
*
|
2002-05-06 |
2005-07-27 |
Nucleonics Inc |
Procedes d'administration d'acides nucleiques
|
US7598421B2
(en)
*
|
2002-05-08 |
2009-10-06 |
Ucl Biomedica Plc |
Materials for the delivery of biologically-active material to cells
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
EA200401565A1
(ru)
*
|
2002-05-24 |
2005-04-28 |
Неофарм, Инк. |
Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
|
NZ571508A
(en)
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
WO2003099830A2
(fr)
*
|
2002-05-24 |
2003-12-04 |
Neopharm, Inc. |
Compositions de cardiolipine, leurs procedes de preparation et d'utilisation
|
DE60334618D1
(de)
|
2002-06-28 |
2010-12-02 |
Protiva Biotherapeutics Inc |
Verfahren und vorrichtung zur herstellung von liposomen
|
US7473527B2
(en)
*
|
2002-07-02 |
2009-01-06 |
The Uab Research Foundation |
Compounds promoting delivery of genes
|
DE60310562T2
(de)
*
|
2002-07-05 |
2007-10-11 |
Lipoxen Technologies Ltd. |
Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
|
US7375093B2
(en)
|
2002-07-05 |
2008-05-20 |
Intrexon Corporation |
Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
WO2004011624A2
(fr)
*
|
2002-07-31 |
2004-02-05 |
Nucleonics, Inc. |
Structures et constructions d'arn a double brin, et leurs procedes de production et d'utilisation
|
US20040034336A1
(en)
*
|
2002-08-08 |
2004-02-19 |
Neal Scott |
Charged liposomes/micelles with encapsulted medical compounds
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7135324B2
(en)
|
2002-09-04 |
2006-11-14 |
The University Of Connecticut |
Viral recombinases, related articles, and methods of use thereof
|
AU2003273271A1
(en)
*
|
2002-09-09 |
2004-03-29 |
The Brigham And Women's Hospital, Inc. |
Genes and proteins altering tau-related neurodegeneration
|
EP1575505A4
(fr)
*
|
2002-09-10 |
2007-01-24 |
Vical Inc |
Vaccins a base de polynucleotides, a optimisation en codon, contre l'infection au bacillus anthracis
|
KR101360955B1
(ko)
|
2002-09-13 |
2014-02-10 |
레플리코르 인코포레이티드 |
비서열 상보적 항바이러스 올리고뉴클레오티드
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US20040053895A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US20060189554A1
(en)
*
|
2002-09-24 |
2006-08-24 |
Russell Mumper |
Nanoparticle-Based vaccine delivery system containing adjuvant
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
US9809654B2
(en)
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
US20050277611A1
(en)
*
|
2002-10-16 |
2005-12-15 |
Neopharm, Inc. |
Cationic cardiolipin analoges and its use thereof
|
US6863731B2
(en)
*
|
2002-10-18 |
2005-03-08 |
Controls Corporation Of America |
System for deposition of inert barrier coating to increase corrosion resistance
|
MXPA05004580A
(es)
*
|
2002-10-29 |
2005-07-26 |
Transave Inc |
Liberacion sostenida de anti - infecciosos.
|
JP3447009B1
(ja)
*
|
2002-10-29 |
2003-09-16 |
實 平垣 |
構築物用構成体およびその製造方法
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
EP1560839A4
(fr)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Composes oligomere chimeres et leur utilisation dans la modulation genique
|
EP1560840B1
(fr)
|
2002-11-05 |
2015-05-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprenant des nucleosides modifies en 2' de substitution destinees a la modulation de gene
|
DK2336318T3
(da)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
Antisense-modulering af apolipoprotein b-ekspression
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質b発現のアンチセンス調節
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
EP1903056A3
(fr)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant
|
US7521187B2
(en)
*
|
2002-12-23 |
2009-04-21 |
Vical Incorporated |
Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
|
US7410795B2
(en)
|
2002-12-23 |
2008-08-12 |
Vical Incorporated |
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
|
CA2508281C
(fr)
*
|
2002-12-23 |
2011-08-09 |
Vical Incorporated |
Procede permettant de produire des medicaments steriles a base de polynucleotides
|
US20070269891A9
(en)
*
|
2003-01-13 |
2007-11-22 |
Yasunobu Tanaka |
Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells
|
US20040138154A1
(en)
|
2003-01-13 |
2004-07-15 |
Lei Yu |
Solid surface for biomolecule delivery and high-throughput assay
|
US7259002B2
(en)
*
|
2003-01-21 |
2007-08-21 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
|
US7304161B2
(en)
*
|
2003-02-10 |
2007-12-04 |
Intrexon Corporation |
Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
|
CA2515484C
(fr)
|
2003-02-11 |
2011-09-20 |
Antisense Therapeutics Ltd |
Modulation de l'expression du recepteur du facteur de croissance i analogue a l'insuline
|
EP1594547A2
(fr)
*
|
2003-02-14 |
2005-11-16 |
University Of South Florida Research Foundation, Inc. |
Derives de chitosane utiles pour le transfert et l'expression de genes
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US7456315B2
(en)
|
2003-02-28 |
2008-11-25 |
Intrexon Corporation |
Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
CA2518475C
(fr)
|
2003-03-07 |
2014-12-23 |
Alnylam Pharmaceuticals, Inc. |
Agents d'arni comprenant des modifications asymetriques
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US20040242502A1
(en)
*
|
2003-04-08 |
2004-12-02 |
Galenica Pharmaceuticals, Inc. |
Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
WO2004094596A2
(fr)
*
|
2003-04-16 |
2004-11-04 |
Wyeth Holdings Corporation |
Nouvelles compositions immunogenes de prevention de traitement de meningococcie
|
EP2666858A1
(fr)
|
2003-04-17 |
2013-11-27 |
Alnylam Pharmaceuticals Inc. |
Agents iARN modifiés
|
AU2004231740A1
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US8080642B2
(en)
*
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
WO2004105697A2
(fr)
*
|
2003-05-22 |
2004-12-09 |
Molecular Transfer, Inc. |
Lipides pour la transfection d'acides nucleiques
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
CN101396555A
(zh)
*
|
2003-06-04 |
2009-04-01 |
坎基股份有限公司 |
用于干扰素治疗的方法和组合物
|
CN1836042A
(zh)
|
2003-06-12 |
2006-09-20 |
原子核物理公司 |
用于基因沉默的hbv和hcv保守序列
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
US20060078560A1
(en)
*
|
2003-06-23 |
2006-04-13 |
Neopharm, Inc. |
Method of inducing apoptosis and inhibiting cardiolipin synthesis
|
SG190613A1
(en)
*
|
2003-07-16 |
2013-06-28 |
Protiva Biotherapeutics Inc |
Lipid encapsulated interfering rna
|
WO2005013901A2
(fr)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
|
WO2005014791A2
(fr)
|
2003-08-08 |
2005-02-17 |
Sangamo Biosciences, Inc. |
Methodes et compositions permettant un clivage et une recombinaison cibles
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7330851B2
(en)
*
|
2003-08-18 |
2008-02-12 |
Eaglehawk, Limited |
Data security through dissembly of data elements or connections between elements
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
CA2536026A1
(fr)
*
|
2003-08-22 |
2005-05-06 |
Nucleonics Inc. |
Systemes d'expression eucaryotes a compartiments multiples
|
US7291604B2
(en)
*
|
2003-09-03 |
2007-11-06 |
The General Hospital Corporation |
Methods of treating restenosis
|
JP4842821B2
(ja)
*
|
2003-09-15 |
2011-12-21 |
プロチバ バイオセラピューティクス インコーポレイティッド |
ポリエチレングリコール修飾脂質化合物およびその使用
|
NZ545134A
(en)
|
2003-09-18 |
2009-06-26 |
Lilly Co Eli |
Modulation of eIF4E expression
|
EP1678315B1
(fr)
|
2003-09-19 |
2011-08-03 |
Sangamo BioSciences, Inc. |
Proteines a doigt de zinc issues du genie genetique pour la regulation de l'expression genique
|
NZ546272A
(en)
|
2003-10-10 |
2009-05-31 |
Alchemia Oncology Pty Ltd |
The modulation of hyaluronan synthesis and degradation in the treatment of disease
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
WO2005048988A1
(fr)
*
|
2003-10-22 |
2005-06-02 |
Neal Scott |
Liposomes/micelles charges a composes medicaux encapsules
|
US8016811B2
(en)
|
2003-10-24 |
2011-09-13 |
Altea Therapeutics Corporation |
Method for transdermal delivery of permeant substances
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
ITMI20032185A1
(it)
*
|
2003-11-12 |
2005-05-13 |
Chemi Spa |
Processo per la sintesi di lipidi cationici.
|
ES2472690T3
(es)
|
2003-11-17 |
2014-07-02 |
Genentech, Inc. |
Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
|
US20050107318A1
(en)
*
|
2003-11-17 |
2005-05-19 |
Samuel Wadsworth |
Methods of treating diabetes and other blood sugar disorders
|
JP4954550B2
(ja)
*
|
2003-12-19 |
2012-06-20 |
大日本住友製薬株式会社 |
新規な核酸導入法
|
SE0303588D0
(sv)
|
2003-12-30 |
2003-12-30 |
Bioactive Polymers Ab C O Lund |
Surface protection of exposed biological tissues
|
EP2363480A3
(fr)
|
2004-01-20 |
2015-10-07 |
Isis Pharmaceuticals, Inc. |
Modulation d'expression de récepteur de glucocorticoïde
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US7432057B2
(en)
*
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
US20050191685A1
(en)
*
|
2004-02-24 |
2005-09-01 |
Innogenetics N.V. |
Method for determining the risk of developing a neurological disease
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1730309B1
(fr)
|
2004-03-15 |
2016-05-04 |
Ionis Pharmaceuticals, Inc. |
Compositions et methodes pour optimiser le clivage d'arn par rnase h
|
ATE480550T1
(de)
|
2004-03-25 |
2010-09-15 |
California Inst Of Techn |
Hybridisierungskettenreaktion
|
AU2005231692B2
(en)
*
|
2004-03-26 |
2011-01-27 |
Curis, Inc. |
RNA interference modulators of Hedgehog signaling and uses thereof
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
WO2005100393A1
(fr)
|
2004-04-08 |
2005-10-27 |
Sangamo Biosciences, Inc. |
Procedes et compositions pour moduler la contractilite cardiaque
|
US20050260652A1
(en)
*
|
2004-04-15 |
2005-11-24 |
The General Hospital Corporation |
Compositions and methods that modulate RNA interference
|
DK1745295T3
(da)
|
2004-04-20 |
2011-01-31 |
Galapagos Nv |
Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
|
MXPA06012162A
(es)
|
2004-04-27 |
2007-03-30 |
Galapagos Nv |
Metodos, agentes y ensayos de seleccion de compuestos para inducir diferenciacion de celulas de mamifero no diferenciadas, en osteoblastos.
|
US7303881B2
(en)
*
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
US7935510B2
(en)
*
|
2004-04-30 |
2011-05-03 |
Intrexon Corporation |
Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
CN107811971B
(zh)
|
2004-05-03 |
2021-10-29 |
益普生生物制药公司 |
用于药物输送的脂质体
|
AU2005248361B2
(en)
|
2004-05-18 |
2010-03-11 |
Vical Incorporated |
Influenza virus vaccine composition and methods of use
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
EP1766035B1
(fr)
|
2004-06-07 |
2011-12-07 |
Protiva Biotherapeutics Inc. |
Arn interferant encapsule dans des lipides
|
JP2008502355A
(ja)
|
2004-06-14 |
2008-01-31 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
変性性及び炎症性疾患の治療に役立つ同定方法及び化合物
|
EP2360474B1
(fr)
|
2004-06-21 |
2013-07-24 |
Galapagos N.V. |
Méthodes et moyens pour le traitement de l'ostéoarthrite
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
EP1773857A4
(fr)
*
|
2004-07-02 |
2009-05-13 |
Protiva Biotherapeutics Inc |
Molecules sirna immunostimulatrices et utilisations de celles-ci
|
US20080299095A1
(en)
*
|
2004-07-09 |
2008-12-04 |
Bc Cancer Agency |
Nup98-Hox Fusions for Expansion of Hemopoietic Stem Cells
|
US7604798B2
(en)
*
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
ATE527281T1
(de)
|
2004-07-16 |
2011-10-15 |
Us Gov Health & Human Serv |
Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
|
US20060051405A1
(en)
*
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
MX2007001679A
(es)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
|
DE602005024015D1
(de)
|
2004-08-23 |
2010-11-18 |
Alnylam Pharmaceuticals Inc |
Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
CA2579677A1
(fr)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Production de proteines: compositions et methodes
|
DE602005027479D1
(de)
|
2004-09-24 |
2011-05-26 |
Alnylam Pharmaceuticals Inc |
Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai
|
EP1799825B1
(fr)
|
2004-10-05 |
2011-06-29 |
The California Institute of Technology |
Acides nucleiques a regulation d'aptameres et leurs utilisations
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
DE602005015241D1
(de)
*
|
2004-10-18 |
2009-08-13 |
Sinai School Medicine |
Hemmung des tumorwachstums und der metastasenbildung mit von atf2 stammenden peptiden
|
AU2005302554A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Idexx Laboratories, Inc. |
Compositions for controlled delivery of pharmaceutically active compounds
|
US20060147449A1
(en)
*
|
2004-11-15 |
2006-07-06 |
Brass Lawrence F |
Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
|
AU2005306533B2
(en)
*
|
2004-11-17 |
2012-05-31 |
Arbutus Biopharma Corporation |
siRNA silencing of apolipoprotein B
|
DE102004057303A1
(de)
*
|
2004-11-26 |
2006-06-01 |
Merck Patent Gmbh |
Stabile Kristallmodifikationen von DOTAP Chlorid
|
WO2006060723A2
(fr)
*
|
2004-12-03 |
2006-06-08 |
Vical Incorporated |
Procedes de production de copolymere sequence/particules amphiphiles
|
EP2316942B1
(fr)
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Sequences vhb et vhc conservees utilisees pour un silençage genique
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
EP1855694B1
(fr)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Composition antisens permettant de traiter une atrophie musculaire
|
EP1869075B1
(fr)
|
2005-02-28 |
2012-04-11 |
Sangamo BioSciences, Inc. |
Methodes et compostions anti-angiogeniques
|
US7727721B2
(en)
|
2005-03-08 |
2010-06-01 |
California Institute Of Technology |
Hybridization chain reaction amplification for in situ imaging
|
KR20070110077A
(ko)
|
2005-03-10 |
2007-11-15 |
제넨테크, 인크. |
혈관 완전성을 조정하기 위한 방법 및 조성물
|
US20090062184A1
(en)
*
|
2005-03-24 |
2009-03-05 |
Dainippon Sumitomo Pharma Co., Ltd. |
Fine particulate preparation comprising complex of nucleic acid molecule and collagen
|
ES2381201T3
(es)
|
2005-03-31 |
2012-05-24 |
Calando Pharmaceuticals, Inc. |
Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
|
US20070026061A1
(en)
*
|
2005-05-25 |
2007-02-01 |
Nahid Ali |
Liposomal formulation and use thereof
|
EP2816118B1
(fr)
|
2005-05-31 |
2018-10-17 |
The Regents of the University of Colorado, a body corporate |
Procédés pour administrer des gènes
|
US8044022B2
(en)
|
2005-06-08 |
2011-10-25 |
Tadeusz Kolodka |
Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
|
CN101437539B
(zh)
*
|
2005-07-05 |
2013-10-02 |
康奈尔研究基金会(有限公司) |
通过干扰cd99l2阻断白细胞迁出和炎症
|
CN101273141B
(zh)
|
2005-07-26 |
2013-03-27 |
桑格摩生物科学股份有限公司 |
外源核酸序列的靶向整合和表达
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US7666584B2
(en)
*
|
2005-09-01 |
2010-02-23 |
Philadelphia Health & Education Coporation |
Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer
|
EP1931789B1
(fr)
|
2005-09-20 |
2016-05-04 |
BASF Plant Science GmbH |
Methodes de regulation de l'expression genique utilisant ta-siarn
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
US7312079B1
(en)
|
2005-10-06 |
2007-12-25 |
Lexicon Pharmaceuticals, Inc. |
Variants of FAM3C
|
ATE526975T1
(de)
|
2005-10-07 |
2011-10-15 |
California Inst Of Techn |
Pkr-aktivierung mittels hybridisierungskettenreaktion
|
WO2007048067A2
(fr)
|
2005-10-21 |
2007-04-26 |
Regents Of The University Of California |
Mutations oncogenes du gene c-kit dans des melanomes
|
AU2006308765B2
(en)
|
2005-11-02 |
2013-09-05 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
US8114440B2
(en)
|
2005-11-16 |
2012-02-14 |
Idexx Laboratories Inc. |
Pharmaceutical compositions for the administration of aptamers
|
US7754679B2
(en)
*
|
2005-11-16 |
2010-07-13 |
Idexx Laboratories, Inc. |
Pharmaceutical compositions for the administration of aptamers
|
EP1966377A2
(fr)
|
2005-11-21 |
2008-09-10 |
Isis Pharmaceuticals, Inc. |
Modulation de l'expression d' eif4e-bp2
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
PL1962805T3
(pl)
|
2005-12-08 |
2017-01-31 |
Insmed Incorporated |
Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych
|
US10647960B2
(en)
*
|
2005-12-13 |
2020-05-12 |
The Trustees Of The University Of Pennsylvania |
Transcriptome transfer produces cellular phenotype conversion
|
US9149543B2
(en)
|
2005-12-15 |
2015-10-06 |
The Trustees Of The University Of Pennsylvania |
Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
WO2007073489A2
(fr)
*
|
2005-12-22 |
2007-06-28 |
Trustees Of Boston University |
Molécules pour administration de gènes et thérapie génique et méthodes d'utilisation de celles-ci
|
BRPI0620125B1
(pt)
|
2005-12-22 |
2022-05-17 |
Vrije Universiteit Brussel |
Método para regulação de redução da função biológica de uma proteína, e método para isolar uma proteína de uma amostra
|
US7951934B2
(en)
|
2006-01-26 |
2011-05-31 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to huntingtin
|
WO2008001166A2
(fr)
*
|
2006-02-07 |
2008-01-03 |
Council Of Scientific & Industrial Research |
Procédé de synthèse d'amphiphiles cationiques de glycomimétiques
|
EP2441770A1
(fr)
|
2006-02-10 |
2012-04-18 |
The University of Cincinnati |
Protéine 1 d'inhibiteur de phosphatase en tant que régulateur de la fonction cardiaque
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
US20070248539A1
(en)
*
|
2006-04-24 |
2007-10-25 |
Shantha West Inc. |
AgRM2 antigen
|
CN101437943A
(zh)
|
2006-05-03 |
2009-05-20 |
波罗的科技发展有限公司 |
牢固结合的碱基-修饰的寡核苷酸和人工核酸酶组合的反义药剂
|
EP2604255B1
(fr)
|
2006-05-05 |
2017-10-25 |
Molecular Transfer, Inc. |
Nouveaux réactifs de transfection de cellules eucaryotes
|
DE602007005634D1
(de)
|
2006-05-25 |
2010-05-12 |
Sangamo Biosciences Inc |
Variante foki-spaltungshälften-domänen
|
GB0610636D0
(en)
|
2006-05-30 |
2006-07-05 |
Univ London |
Materials and complexes for the delivery of biologically-active material to cells
|
JP2009538924A
(ja)
|
2006-06-01 |
2009-11-12 |
エラン ファーマシューティカルズ,インコーポレイテッド |
Appの神経活性断片
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
US20080004410A1
(en)
*
|
2006-06-30 |
2008-01-03 |
Yu-Chin Lai |
Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same
|
JP5072275B2
(ja)
|
2006-07-03 |
2012-11-14 |
テルモ株式会社 |
閉鎖小胞の分離方法、製剤の製造方法および評価方法
|
WO2008011473A2
(fr)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions et leurs utilisations liées à l'hbxip
|
RU2500815C2
(ru)
*
|
2006-07-28 |
2013-12-10 |
Санофи-Авентис |
Композиция и способ лечения опухолей
|
ES2658239T3
(es)
|
2006-10-19 |
2018-03-08 |
Csl Limited |
Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina-13
|
JP2010507365A
(ja)
|
2006-10-19 |
2010-03-11 |
メルク アンド カンパニー インコーポレイテッド |
抗IL−13Rα1抗体およびその使用
|
WO2008070350A2
(fr)
*
|
2006-10-27 |
2008-06-12 |
The Board Of Regents Of The University Of Texas System |
Procédés et compositions liés aux enveloppements de déshydrons
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
WO2008152446A2
(fr)
|
2006-11-27 |
2008-12-18 |
Patrys Limited |
Nouvelle cible de peptide glycosylé dans des cellules néoplasiques
|
EP1938843A1
(fr)
*
|
2006-12-19 |
2008-07-02 |
Novosom AG |
Lipides et ensembles lipidiques comprenant des éléments d'amélioration de la transfection
|
AR064642A1
(es)
*
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
EP2118118B1
(fr)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Apport cellulaire médié d'oligonucléotides de lna
|
US20100093836A1
(en)
|
2007-01-29 |
2010-04-15 |
Isis Pharmaceuticals, Inc |
Compounds and methods for modulating protein expression
|
JP5357782B2
(ja)
|
2007-02-21 |
2013-12-04 |
バクシネックス インコーポレーティッド |
抗原負荷CD1d分子によるNKT細胞活性の調節
|
AU2008218199B2
(en)
|
2007-02-22 |
2013-10-31 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
PL2118300T3
(pl)
|
2007-02-23 |
2015-11-30 |
Prothena Biosciences Ltd |
Zapobieganie i leczenie synukleinopatii i amyloidozy
|
PT3067066T
(pt)
|
2007-02-23 |
2019-06-17 |
Univ California |
Prevenção e tratamento da doença sinucleinopática e amiloidogénica
|
US20080299182A1
(en)
*
|
2007-03-01 |
2008-12-04 |
Shuyuan Zhang |
Methods and formulations for topical gene therapy
|
WO2008106658A2
(fr)
|
2007-03-01 |
2008-09-04 |
California Institute Of Technology |
Arni déclenché
|
US8877206B2
(en)
*
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
DE102007015598A1
(de)
*
|
2007-03-29 |
2008-10-02 |
Heinrich-Heine-Universität Düsseldorf |
Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
|
WO2008124768A1
(fr)
|
2007-04-09 |
2008-10-16 |
The General Hospital Corporation |
Protéines de fusion d'hémojuvéline et utilisations de celles-ci
|
WO2008137717A1
(fr)
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions de médicaments multicationiques pour réduire des interactions avec des biomolécules polyanioniques et leurs procédés et utilisations
|
HUE040417T2
(hu)
|
2007-05-04 |
2019-03-28 |
Marina Biotech Inc |
Aminosavlipidek és alkalmazásuk
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
MY149171A
(en)
*
|
2007-05-16 |
2013-07-31 |
Mat Malta Advanced Technologies Ltd |
Treatment and prevention of influenza
|
EP2155770B1
(fr)
|
2007-05-16 |
2013-10-16 |
California Institute of Technology |
Motif polyvalent d'acide nucléique en épingle à cheveux pour la programmation de voies d'auto-assemblage biomoléculaire
|
WO2008148057A2
(fr)
|
2007-05-23 |
2008-12-04 |
Vical Incorporated |
Compositions et procédés pour améliorer la réponse immunitaire à des vaccins
|
RU2490253C2
(ru)
|
2007-05-29 |
2013-08-20 |
Интрексон Корпорейшн |
Хиральные диацилгидразиновые лиганды для модуляции экспрессии экзогенных генов с помощью экдизон-рецепторного комплекса
|
US20080312174A1
(en)
*
|
2007-06-05 |
2008-12-18 |
Nitto Denko Corporation |
Water soluble crosslinked polymers
|
US8637257B2
(en)
|
2007-06-20 |
2014-01-28 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
|
US20090069266A1
(en)
*
|
2007-06-27 |
2009-03-12 |
Northwestern University |
Methods and compositions for nucleic acid transfer into cells
|
JP5770471B2
(ja)
|
2007-07-12 |
2015-08-26 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
α−1,6−フコシルトランスフェラーゼ(FUT8)遺伝子発現を不活性化するための方法および組成物
|
WO2009011855A2
(fr)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Sélection de domaines de capteur à base d'acide nucléique dans une plate-forme d'échange d'acide nucléique
|
US8828960B2
(en)
*
|
2007-07-17 |
2014-09-09 |
Idexx Laboratories, Inc. |
Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
|
NZ583430A
(en)
|
2007-08-23 |
2012-06-29 |
Intrexon Corp |
Methods and compositions for diagnosing disease via detecting reporter gene expression
|
US8367815B2
(en)
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
EP2183355B1
(fr)
*
|
2007-09-17 |
2016-01-27 |
Rohm and Haas Company |
Compositions et procedes pour la modification de reponses physiologiques chez les plantes
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
CA2715080C
(fr)
|
2007-09-28 |
2021-09-28 |
Intrexon Corporation |
Constructions et bioreacteurs de commutation de gene theapeutique destines a l'expression de molecules biotherapeutiques, et utilisation de ceux-ci
|
JP2010539978A
(ja)
|
2007-10-02 |
2010-12-24 |
アムジェン インコーポレイテッド |
マイクロ−rnaおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
|
ES2629440T5
(es)
|
2007-10-04 |
2020-11-20 |
Zymogenetics Inc |
zB7H6 miembro de la familia B7 y composiciones y métodos relacionados
|
HUE024479T2
(en)
*
|
2007-10-08 |
2016-01-28 |
Intrexon Corp |
Genetically altered dendritic cells and uses for cancer treatment
|
GB0720486D0
(en)
*
|
2007-10-19 |
2007-11-28 |
Univ Edinburgh |
Cationic lipids
|
EP2217721A4
(fr)
*
|
2007-10-29 |
2013-01-09 |
Univ California |
Thérapie génique pour l'ostéoarthrite
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
DE102008023913A1
(de)
|
2008-05-16 |
2009-11-19 |
Biontex Laboratories Gmbh |
Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
|
WO2009065618A2
(fr)
|
2007-11-22 |
2009-05-28 |
Biontex Laboratories Gmbh |
Amélioration de résultats de transfection de systèmes de livraison de gènes non viraux par action sur le système immunitaire inné
|
DE102008016275A1
(de)
|
2008-03-28 |
2009-11-19 |
Biontex Laboratories Gmbh |
Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
|
DE102007056488A1
(de)
|
2007-11-22 |
2009-07-23 |
Biontex Laboratories Gmbh |
Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
|
CA2930393C
(fr)
|
2007-12-04 |
2022-11-29 |
Alnylam Pharmaceuticals, Inc. |
Conjugues glucidiques utilises en tant qu'agents d'administration pour des oligonucleotides
|
US9029524B2
(en)
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
SG10201408162PA
(en)
|
2007-12-11 |
2015-01-29 |
Scripps Research Inst |
Compositions and methods related to mrna translational enhancer elements
|
US8779088B2
(en)
|
2007-12-17 |
2014-07-15 |
Marfl Ab |
Vaccine for the treatment of Mycobacterium related disorders
|
AU2008342535B2
(en)
|
2007-12-27 |
2015-02-05 |
Arbutus Biopharma Corporation |
Silencing of polo-like kinase expression using interfering RNA
|
EP2730659A3
(fr)
|
2007-12-28 |
2016-01-13 |
Prothena Biosciences Limited |
Traitement et Prophylaxie de L'amylose
|
EP2247729B1
(fr)
|
2008-02-11 |
2019-05-01 |
Phio Pharmaceuticals Corp. |
Polynucléotides d'arni modifiés et leurs utilisations
|
US8497364B2
(en)
*
|
2008-02-27 |
2013-07-30 |
California Institute Of Technology |
Triggered RNAi
|
US20110045001A1
(en)
*
|
2008-03-28 |
2011-02-24 |
Biontex Laboratories Gmbh |
Transfection results of non-viral gene delivery systems by influencing of the innate immune system
|
WO2009123764A2
(fr)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions et utilisation d'inhibiteurs d'epas1
|
CA2721183C
(fr)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Delivrance specifique a un site d'acides nucleiques en combinant des ligands de ciblage avec des composants endosomolytiques
|
CA2721333C
(fr)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Nouvelles formulations lipidiques pour l'administration d'acides nucleiques
|
CA2721380A1
(fr)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Reduction au silence de l'expression du gene csn5 au moyen d'arn interferant
|
WO2009129227A1
(fr)
|
2008-04-17 |
2009-10-22 |
Pds Biotechnology Corporation |
Stimulation de réponse immunitaire par des énantiomères de lipides cationiques
|
US20100021904A1
(en)
*
|
2008-05-21 |
2010-01-28 |
Pierce Niles A |
Shielded cross-linking probes
|
US20100021901A1
(en)
*
|
2008-05-22 |
2010-01-28 |
Peng Yin |
Compositions and methods for detecting analytes
|
US8241854B2
(en)
*
|
2008-05-22 |
2012-08-14 |
California Institute Of Technology |
Triggered RNAi
|
JP2011521649A
(ja)
|
2008-05-30 |
2011-07-28 |
イェール ユニバーシティー |
遺伝子発現を改変するための標的化オリゴヌクレオチド組成物
|
AU2009258117B2
(en)
|
2008-06-10 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for generation of Bax- and Bak-deficient cell lines
|
CN102316894A
(zh)
|
2008-06-20 |
2012-01-11 |
惠氏有限责任公司 |
来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
KR101759586B1
(ko)
|
2008-08-22 |
2017-07-19 |
상가모 테라퓨틱스, 인코포레이티드 |
표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
|
DK2331141T3
(en)
|
2008-08-25 |
2016-04-04 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
|
EP2816113A3
(fr)
|
2008-09-11 |
2015-03-25 |
Galapagos N.V. |
Procédés d'identification et composés utiles pour augmenter l'activité fonctionnelle et l'expression de surface cellulaire du régulateur de la conductance de trans-membrane de la fibrose kystique mutante associée à la mucoviscidose
|
US8796443B2
(en)
|
2008-09-22 |
2014-08-05 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
AU2009303345B2
(en)
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
WO2010045512A2
(fr)
|
2008-10-16 |
2010-04-22 |
Mdrna , Inc. |
Procédés et compositions pour une administration liposomale et efficace de produits thérapeutiques de silençage de gène
|
CA2741691C
(fr)
|
2008-11-05 |
2019-11-26 |
Ingrid Lea Dodge |
Composition immunogene a multiples composants pour la prevention d'une maladie streptococcique beta-hemolytique (bhs)
|
WO2010059226A2
(fr)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition de map4k4 via arni
|
US20110237649A1
(en)
|
2008-12-04 |
2011-09-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
US20110294870A1
(en)
|
2008-12-04 |
2011-12-01 |
Opko Curna, Llc |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
CA2745031C
(fr)
|
2008-12-04 |
2018-08-14 |
Sangamo Biosciences, Inc. |
Edition de genome chez des rats au moyen de nucleases en doigt de zinc
|
US8921329B2
(en)
|
2008-12-04 |
2014-12-30 |
Curna, Inc. |
Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
FR2941152B1
(fr)
*
|
2009-01-20 |
2013-10-18 |
Centre Nat Rech Scient |
Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
|
EP2393506B1
(fr)
|
2009-02-04 |
2018-03-28 |
Sangamo Therapeutics, Inc. |
Procédés et compositions pour traiter des neuropathies
|
WO2010090762A1
(fr)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Duplexes d'arn avec régions de nucléotide phosphorothioate à brin unique pour fonctionnalité supplémentaire
|
KR101805199B1
(ko)
|
2009-02-12 |
2017-12-05 |
큐알엔에이, 인크. |
신경교세포 유래된 신경영양성 인자 (gdnf)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (gdnf) 관련된 질환의 치료
|
DK2396038T3
(en)
|
2009-02-12 |
2016-02-01 |
Curna Inc |
TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
WO2010096561A1
(fr)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Protéines gag du vih/vis de synthèse et leurs utilisations
|
WO2010094732A1
(fr)
|
2009-02-19 |
2010-08-26 |
Biofocus Dpi B.V. |
Procédé pour identifier des composés utiles pour diagnostiquer et traiter des maladies impliquant une inflammation
|
US20120004160A1
(en)
|
2009-02-19 |
2012-01-05 |
Glaxo Group Ltd. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
JP2012517821A
(ja)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
|
WO2010102058A2
(fr)
|
2009-03-04 |
2010-09-10 |
Curna, Inc. |
Traitement de maladies liées à sirtuine 1 (sirt1) par inhibition d'un produit de transcription antisens naturel de sirt 1
|
EP2408919B1
(fr)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Traitement de maladies associées au facteur nucléaire 2 similaire au dérivé d'érythroïde 2 (nrf2) par inhibition de produit de transcription antisens naturel pour nrf2
|
EP2408920B1
(fr)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Traitement des maladies associées à l'homologue du delta-like 1 (dlk1) par inhibition du transcrit antisens naturel de dlk1
|
US8993509B2
(en)
|
2009-03-31 |
2015-03-31 |
Robert Zimmerman |
Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
|
WO2010112569A1
(fr)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation de lipase de triglycérides d'adipose pour la prévention et le traitement d'une cachexie, d'une perte de poids et d'une atrophie musculaire et procédés de criblage s'y rapportant
|
EP2414829A1
(fr)
|
2009-04-01 |
2012-02-08 |
Galapagos N.V. |
Procédés et moyens de traitement de l'arthrite
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
WO2010117464A1
(fr)
|
2009-04-09 |
2010-10-14 |
Sangamo Biosciences, Inc. |
Intégration ciblée dans des cellules souches
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
CA2758542A1
(fr)
|
2009-04-17 |
2010-10-21 |
New York University |
Peptides ciblant les recepteurs de la famille du tnf et contrant l'action du tnf, compositions, methodes et utilisations afferentes
|
EP3524275A1
(fr)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Suppression immunitaire innée permettant la distribution répétée de longues molécules d'arn
|
US20100273203A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Board Of Trustees Of The University Of Arkansas |
Methods and compositions for detecting metabolites
|
WO2010126066A1
(fr)
|
2009-04-27 |
2010-11-04 |
協和発酵キリン株式会社 |
Anticorps anti-il-3rα destiné à être utilisé dans le traitement d'hématomes
|
US8044215B2
(en)
*
|
2009-04-29 |
2011-10-25 |
Juvaris Biotherapeutics, Inc. |
Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds
|
ES2661787T3
(es)
|
2009-05-01 |
2018-04-04 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con hemoglobina (hbf/hbg) por inhibición de transcrito antisentido natural para hbf/hbg
|
WO2010129746A2
(fr)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Traitement de maladies liées à la tristétraproline (ttp) par l'inhibition d'un transcrit antisens naturel de ttp
|
WO2010129799A2
(fr)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Traitement de maladies associées aux gènes du métabolisme et du transport des lipides par inhibition de transcrit antisens naturel d'un gène du métabolisme et du transport des lipides
|
EP2430168B1
(fr)
|
2009-05-16 |
2016-12-21 |
Kunyuan Cui |
Compositions comprenant des amphiphiles et des colipides cationiques pour administrer des molécules thérapeutiques
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
WO2010135695A2
(fr)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
Traitement des maladies liées au facteur de transcription e3 (tfe3) et au substrat récepteur d'insuline 2 (irs2) par inhibition du transcript antisens naturel du tfe3
|
US8791085B2
(en)
|
2009-05-28 |
2014-07-29 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
JP6166041B2
(ja)
|
2009-06-15 |
2017-07-19 |
バレリオン セラピューティクス, エルエルシー |
ミオチューブラリン1(mtm1)ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物
|
EP2443237B1
(fr)
|
2009-06-16 |
2017-02-22 |
CuRNA, Inc. |
Traitement de maladies liées au gène du collagène par inhibition d'un produit de transcription antisens naturel à un gène du collagène
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
WO2010151671A2
(fr)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Traitement de maladies associées au récepteur de facteur nécrosant des tumeurs 2 (tnfr2) par inhibition de la transcription antisens naturelle de tnfr2
|
EP2446037B1
(fr)
|
2009-06-26 |
2016-04-20 |
CuRNA, Inc. |
Traitement de maladies associées aux gènes liés au syndrome de down par inhibition des gènes liés au syndrome de down médiée par le produit de transcription antisens naturel
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
ES2527220T5
(es)
|
2009-07-09 |
2018-06-05 |
Marina Biotech, Inc. |
Liposomas anfóteros que comprenden lípidos imino
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
EP2461819A4
(fr)
|
2009-07-28 |
2013-07-31 |
Sangamo Biosciences Inc |
Procédés et compositions de traitement de troubles de répétition tri-nucléotidique
|
DK2462230T3
(en)
|
2009-08-03 |
2015-10-19 |
Recombinetics Inc |
METHODS AND COMPOSITIONS FOR TARGETED RE-MODIFICATION
|
WO2011015573A1
(fr)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Cibles et composés moléculaires, et procédés pour les identifier, utiles dans le traitement de maladies neurodégénératives
|
WO2011015572A1
(fr)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Cibles et composés moléculaires, et procédés pour leur identification utiles dans le traitement de maladies neurodégénératives
|
WO2011017516A2
(fr)
|
2009-08-05 |
2011-02-10 |
Curna, Inc. |
Traitement de maladies liées à un gène de linsuline (ins) par inhibition du transcrit antisens naturel d'un gène de l'insuline (ins)
|
US8410064B2
(en)
*
|
2009-08-24 |
2013-04-02 |
The Board Of Trustees Of The University Of Arkansas |
Classical cannabinoid metabolites and methods of use thereof
|
CA2771172C
(fr)
|
2009-08-25 |
2021-11-30 |
Opko Curna, Llc |
Traitement de maladies associees a la proteine d'activation de gtpase contenant un motif iq (iqgap), par inhibition d'un transcrit antisens naturel de iqgap
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US9222086B2
(en)
|
2009-09-23 |
2015-12-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
EP3252068A3
(fr)
|
2009-10-12 |
2018-03-14 |
Larry J. Smith |
Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
MX2012004617A
(es)
|
2009-10-22 |
2012-05-08 |
Genentech Inc |
Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
|
WO2011056682A1
(fr)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Lipides à têtes polaires inversées, compositions particulaires lipidiques comprenant les lipides à têtes polaires inversées, et procédés d'administration d'acides nucléiques
|
WO2011056234A1
(fr)
|
2009-11-06 |
2011-05-12 |
Fibrogen, Inc. |
Traitement de troubles induits par un rayonnement
|
US9556272B2
(en)
|
2009-11-11 |
2017-01-31 |
The Trustees Of The University Of Pennsylvania |
Anti-TEM1 antibodies and uses thereof
|
MX338694B
(es)
|
2009-11-30 |
2016-04-27 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
PT3338765T
(pt)
|
2009-12-01 |
2019-03-18 |
Translate Bio Inc |
Derivado de esteróide adequado para a administração de arnm em doenças genéticas humanas
|
MX2012006580A
(es)
|
2009-12-11 |
2012-09-28 |
Genecode As |
Metodo para facilitar la sobrevivencia de celulas neurales usando mimeticos de ligandos (gfl) de la familia gdnf o activadores de la ruta de señalizacion de ret.
|
JP6025567B2
(ja)
|
2009-12-16 |
2016-11-16 |
カッパーアールエヌエー,インコーポレイテッド |
膜結合転写因子ペプチダーゼ、部位1(mbtps1)に対する天然アンチセンス転写物の阻害によるmbtps1関連性疾患の治療
|
JP6031356B2
(ja)
|
2009-12-23 |
2016-11-24 |
カッパーアールエヌエー,インコーポレイテッド |
Ucp2に対する天然アンチセンス転写産物の阻害による脱共役タンパク質2(ucp2)関連疾患の治療
|
EP2516648B1
(fr)
|
2009-12-23 |
2017-11-08 |
CuRNA, Inc. |
Traitement de maladies associées au facteur de croissance des hépatocytes (hgf) par inhibition de la transcription antisens naturelle en hgf
|
KR101853508B1
(ko)
|
2009-12-29 |
2018-06-20 |
큐알엔에이, 인크. |
종양 단백질 63 (p63)에 대한 천연 안티센스 전사체의 억제에 의한 p63에 관련된 질환의 치료
|
CA2785173A1
(fr)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Traitement de maladies liees au facteur respiratoire nucleaire 1 (nrf1) par l'inhibition du produit de transcription antisens naturel de nrf1
|
NO2521784T3
(fr)
|
2010-01-04 |
2018-05-05 |
|
|
CN102822342B
(zh)
|
2010-01-06 |
2017-05-10 |
库尔纳公司 |
通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
US8883739B2
(en)
|
2010-01-19 |
2014-11-11 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
CA2787494C
(fr)
|
2010-01-22 |
2019-09-17 |
Dow Agrosciences Llc |
Alteration genomique ciblee
|
US8946182B2
(en)
|
2010-01-25 |
2015-02-03 |
Curna, Inc. |
Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
|
AU2011213242B2
(en)
|
2010-02-08 |
2015-01-29 |
Sangamo Therapeutics, Inc. |
Engineered cleavage half-domains
|
WO2011100058A1
(fr)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Modification génomique ciblée avec des molécules donneuses partiellement monocaténaires
|
EP2539452B1
(fr)
|
2010-02-22 |
2016-07-27 |
CuRNA, Inc. |
Traitement de maladies liées à la pyrroline-5-carboxylate réductase 1 (pycr1) par inhibition du produit de transcription antisens naturel de pycr1
|
PE20130214A1
(es)
|
2010-02-23 |
2013-03-11 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
WO2011109427A2
(fr)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Amélioration de l'activité biologique de parni par modulation de son profil thermodynamique
|
US20130047297A1
(en)
|
2010-03-08 |
2013-02-21 |
Robert D. Sammons |
Polynucleotide molecules for gene regulation in plants
|
CA2793521A1
(fr)
|
2010-03-19 |
2011-09-22 |
University Of South Alabama |
Utilisation de gli1 antisens afin de reduire la dose d'un compose therapeutique pour traiter un cancer a traiter
|
RU2612788C2
(ru)
|
2010-03-23 |
2017-03-13 |
Интрексон Корпорейшн |
Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
|
KR102453078B1
(ko)
|
2010-03-24 |
2022-10-11 |
피오 파마슈티칼스 코프. |
진피 및 섬유증성 적응증에서의 rna 간섭
|
EP2550000A4
(fr)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Composés d'arni de taille réduite s'auto-administrant
|
US9247720B2
(en)
|
2010-03-24 |
2016-02-02 |
Institut National de la Santé et de la Recherche Médicale |
Primate model from the family cercopithecidae infected by a HBV strain of human genotype
|
WO2011119871A1
(fr)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Arn interférant dans des indications oculaires
|
CA2793959C
(fr)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Glycoproteines du cmv et vecteurs recombines
|
WO2011120023A1
(fr)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Composés d'acide nucléique pour inhiber l'expression de gène de survivine et utilisations de ceux-ci
|
US8883218B2
(en)
|
2010-03-26 |
2014-11-11 |
The Board Of Trustees Of The University Of Arkansas |
Anti-cancer nanoparticle compositions and methods of use
|
RU2610661C2
(ru)
|
2010-04-09 |
2017-02-14 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
|
US8790621B2
(en)
*
|
2010-04-12 |
2014-07-29 |
Iowa State University Research Foundation, Inc. |
Nanoparticles and nanoparticle compositions
|
AU2011239386B2
(en)
|
2010-04-16 |
2015-03-19 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using FGF
|
WO2011133584A2
(fr)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Composés de type acide nucléique pour inhiber l'expression du gène hras et leurs utilisations
|
US20130129811A1
(en)
|
2010-04-28 |
2013-05-23 |
Takeshi Kuboyama |
Cationic lipid
|
WO2011139843A2
(fr)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Compositions multi-siarn pour la réduction de l'expression génique
|
JP5902616B2
(ja)
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
BR112012027547B1
(pt)
|
2010-04-29 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
|
EP2566893A1
(fr)
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
JP2013525483A
(ja)
|
2010-05-03 |
2013-06-20 |
カッパーアールエヌエー,インコーポレイテッド |
サーチュイン(sirt)に対する天然アンチセンス転写物の阻害によるサーチュイン(sirt)関連疾患の治療
|
DK2569430T3
(en)
|
2010-05-12 |
2019-02-04 |
Univ Columbia |
PROCEDURES FOR MANUFACTURING ENTEROENDOCRIN CELLS WHICH MANUFACTURE AND SECRET INSULIN
|
WO2011141704A1
(fr)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Nouveaux lipides cationiques cycliques et procédés d'utilisation
|
CA2799091A1
(fr)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Lipides cationiques et procedes d'utilisation de ceux-ci
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
WO2011146121A1
(fr)
|
2010-05-17 |
2011-11-24 |
Sangamo Biosciences, Inc. |
Nouvelles protéines se liant à l'adn et leurs utilisations
|
US8658780B2
(en)
|
2010-05-18 |
2014-02-25 |
California Institute Of Technology |
Triggered covalent probes for imaging and silencing genetic expression
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
WO2011156356A1
(fr)
|
2010-06-09 |
2011-12-15 |
Zymogenetics, Inc. |
Protéines de fusion vstm3 dimères et compositions et procédés connexes
|
CA2802994A1
(fr)
|
2010-06-17 |
2011-12-22 |
The United States Of America As Represented By The Secretary, National I Nstitutes Of Health |
Compositions et procedes pour traiter des affections inflammatoires
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
MX2013000164A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
|
EP2590670B1
(fr)
|
2010-07-06 |
2017-08-23 |
GlaxoSmithKline Biologicals SA |
Procédé pour induire une réponse immunitaire par administration d'arn
|
JP5940064B2
(ja)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
低用量のrnaを用いた大型哺乳動物の免疫化
|
JP6025721B2
(ja)
|
2010-07-06 |
2016-11-16 |
ノバルティス アーゲー |
カチオン性水中油型エマルジョン
|
EP2593547B1
(fr)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Traitement de maladies liées à « discs large homolog » (dlg) par inhibition de transcrit antisens naturel de dlg
|
US8877438B2
(en)
|
2010-07-20 |
2014-11-04 |
California Institute Of Technology |
Self-assembled polynucleotide structure
|
US9834439B2
(en)
|
2010-07-20 |
2017-12-05 |
California Institute Of Technology |
Biomolecular self-assembly
|
US8962241B2
(en)
|
2010-07-20 |
2015-02-24 |
California Institute Of Technology |
Triggered molecular geometry based bioimaging probes
|
US9057057B2
(en)
|
2010-07-27 |
2015-06-16 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
EP3831406B1
(fr)
|
2010-08-23 |
2024-06-05 |
Wyeth LLC |
Formulations stables des antigènes rlp2086 de neisseria meningitidis
|
HRP20220695T1
(hr)
|
2010-08-31 |
2022-07-08 |
Glaxosmithkline Biologicals Sa |
Pegilirani liposomi za isporuku rnk kodirane za imunogen
|
AU2011300409B2
(en)
|
2010-09-10 |
2015-03-26 |
Wyeth Llc |
Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
|
WO2012035557A1
(fr)
|
2010-09-14 |
2012-03-22 |
Council Of Scientific & Industrial Research |
Nouveaux amphiphiles cationiques à têtes polaires imitant la mannose, et leurs méthodes de préparation
|
US9566352B2
(en)
|
2010-09-27 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
WO2012047968A2
(fr)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened et ses procédés d'utilisation
|
CN103210086B
(zh)
|
2010-10-06 |
2017-06-09 |
库尔纳公司 |
通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
|
KR102162111B1
(ko)
|
2010-10-11 |
2020-10-07 |
노파르티스 아게 |
항원 전달 플랫폼
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
CN103201387B
(zh)
|
2010-10-27 |
2018-02-02 |
库尔纳公司 |
通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
|
US20140134181A1
(en)
|
2010-11-05 |
2014-05-15 |
Kenneth E. Lipson |
Treatment Method For Lung Remodeling Diseases
|
JP6071893B2
(ja)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療
|
JP2014504184A
(ja)
|
2010-12-01 |
2014-02-20 |
スパイナル・モデュレーション・インコーポレイテッド |
神経構造への薬剤の直接送達
|
NZ611427A
(en)
|
2010-12-06 |
2015-08-28 |
Penn State Res Found |
Compositions and methods relating to proliferative diseases
|
CN105821078A
(zh)
|
2010-12-09 |
2016-08-03 |
巴斯德研究所 |
用于获得高产量重组蛋白表达的基于mgmt的方法
|
US9095598B2
(en)
|
2010-12-28 |
2015-08-04 |
The Board Of Trustees Of The University Of Arkansas |
Stilbenoid derivatives and their uses
|
EP2670426B1
(fr)
|
2011-01-31 |
2017-05-10 |
The General Hospital Corporation |
Molécules trail multimodales et leurs utilisations en thérapies cellulaires
|
TWI593416B
(zh)
|
2011-02-02 |
2017-08-01 |
艾克厘德製藥公司 |
利用針對結締組織生長因子(ctgf)目標之反義化合物治療瘢痕或肥厚性疤痕之方法
|
WO2012109495A1
(fr)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cibles cellulaires de thiazolidinediones
|
EP2492279A1
(fr)
|
2011-02-25 |
2012-08-29 |
Laboratorios Del. Dr. Esteve, S.A. |
Procédé de sélection rapide d'immunogène par expression à la surface du lentivirus.
|
EP2681327B1
(fr)
|
2011-03-04 |
2018-11-21 |
Intrexon Corporation |
Vecteurs exprimant une protéine de façon conditionnelle
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
WO2012135696A2
(fr)
|
2011-04-01 |
2012-10-04 |
University Of South Alabama |
Procédés et compositions pour le diagnostic, la classification et le traitement du cancer
|
US8658783B2
(en)
|
2011-04-13 |
2014-02-25 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
WO2012149515A2
(fr)
*
|
2011-04-29 |
2012-11-01 |
Northwestern University |
Nouveaux échafaudages à base d'un peptide mimétique de vegf pour une angiogenèse thérapeutique, et procédés pour leur utilisation
|
SG10201706859QA
(en)
|
2011-05-20 |
2017-09-28 |
Merck Patent Gmbh |
Stable crystal modifications of dotap chloride
|
CA2836494C
(fr)
|
2011-05-24 |
2023-01-03 |
Biontech Ag |
Vaccins individualises pour le cancer
|
BR112013031553A2
(pt)
|
2011-06-08 |
2020-11-10 |
Shire Human Genetic Therapies, Inc. |
composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
|
CN103620036B
(zh)
|
2011-06-09 |
2016-12-21 |
库尔纳公司 |
通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
|
HUE037408T2
(hu)
|
2011-06-10 |
2018-08-28 |
Univ Oregon Health & Science |
CMV glikoproteinek és rekombináns vektorok
|
CA2839437A1
(fr)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Modulation antisens de l'expression du recepteur 4 du facteur de croissance fibroblastique
|
RU2711799C2
(ru)
|
2011-06-21 |
2020-01-22 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
EP2729165B1
(fr)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Compositions de combinaisons immunogènes et utilisations de celles-ci
|
MX350198B
(es)
|
2011-07-06 |
2017-08-30 |
Novartis Ag |
Emulsiones aceite en agua que contienen acidos nucleicos.
|
WO2013006837A1
(fr)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Emulsions huile dans eau cationiques
|
EP2546358A1
(fr)
|
2011-07-15 |
2013-01-16 |
Laboratorios Del. Dr. Esteve, S.A. |
Procédés et réactifs pour un contrôle efficace de la progression du VIH
|
WO2013012674A1
(fr)
|
2011-07-15 |
2013-01-24 |
The General Hospital Corporation |
Procédés d'assemblage d'effecteurs de type activateur de la transcription
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
US10760086B2
(en)
|
2011-09-13 |
2020-09-01 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10806146B2
(en)
|
2011-09-13 |
2020-10-20 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10829828B2
(en)
|
2011-09-13 |
2020-11-10 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
AU2012308694B2
(en)
|
2011-09-13 |
2018-06-14 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
HUE036177T2
(hu)
|
2011-09-19 |
2018-06-28 |
Axon Neuroscience Se |
TAU-mediált patológia protein alapú terápiája és diagnózisa Alzheimer-betegségben
|
WO2013043569A1
(fr)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Immunothérapie combinée à action antitumorale synergique faisant appel à des alloantigènes
|
KR101840512B1
(ko)
|
2011-09-20 |
2018-03-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Gcgr 발현의 안티센스 조절
|
WO2013043720A1
(fr)
|
2011-09-20 |
2013-03-28 |
The University Of North Carolina At Chapel Hill |
Régulation de canaux sodiques par des protéines plunc
|
AU2012312260B2
(en)
|
2011-09-21 |
2017-08-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
WO2013053765A1
(fr)
|
2011-10-11 |
2013-04-18 |
Proyecto De Biomedicina Cima, S.L. |
Modèle animal non humain de lymphome du tissu lymphoïde associé aux muqueuses (malt)
|
KR20140084232A
(ko)
|
2011-10-25 |
2014-07-04 |
아이시스 파마수티컬즈 인코포레이티드 |
Gccr 발현의 안티센스 조절
|
EP2586461A1
(fr)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Particules virales dérivées d'un virus enveloppé
|
JP2013095755A
(ja)
|
2011-11-02 |
2013-05-20 |
Kyowa Hakko Kirin Co Ltd |
カチオン性脂質
|
KR20220045091A
(ko)
|
2011-11-18 |
2022-04-12 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법
|
EA201490993A1
(ru)
|
2011-11-18 |
2014-09-30 |
Элнилэм Фармасьютикалз, Инк. |
МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
|
CA2856742A1
(fr)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipides biodegradables pour l'administration d'agents actifs
|
US9463247B2
(en)
*
|
2011-12-07 |
2016-10-11 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
ES2648899T3
(es)
|
2011-12-09 |
2018-01-08 |
Institut Pasteur |
Inmunoensayo de cribado múltiplex
|
JP6182458B2
(ja)
|
2011-12-12 |
2017-08-16 |
協和発酵キリン株式会社 |
カチオン性脂質の組み合わせを含有する脂質ナノ粒子
|
EP2792367A4
(fr)
|
2011-12-12 |
2015-09-30 |
Kyowa Hakko Kirin Co Ltd |
Nanoparticules lipidiques pour système d'administration de médicament contenant des lipides cationiques
|
EP2791160B1
(fr)
*
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Compositions de mrna modifiés
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
HUE041509T2
(hu)
|
2011-12-22 |
2019-05-28 |
Janssen Biopharma Inc |
Szubsztituált nukleozidok, nukleotidok és ezek analógjai
|
WO2013103401A1
(fr)
|
2012-01-06 |
2013-07-11 |
University Of South Alabama |
Procédés et compositions pour le traitement du cancer
|
EP3381461B1
(fr)
|
2012-01-09 |
2021-03-10 |
Serpin Pharma, LLC |
Peptides et leurs procédés d'utilisation
|
EP3988104A1
(fr)
|
2012-02-24 |
2022-04-27 |
Arbutus Biopharma Corporation |
Lipides cationiques de trialkyle et leurs procédés d'utilisation
|
BR112014021104B1
(pt)
|
2012-02-29 |
2023-03-28 |
Sangamo Biosciences, Inc |
Proteína de fusão de ocorrência não natural compreendendo um domínio de ligação de dna de dedo de zinco manipulado que se liga a um gene htt, seu uso, método in vitro de modificação da expressão de um gene htt em uma célula, e método de geração de um sistema modelo para o estudo da doença de huntington
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
MX351993B
(es)
|
2012-03-09 |
2017-11-03 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas.
|
TR201815503T4
(tr)
|
2012-03-15 |
2018-11-21 |
Curna Inc |
Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
WO2013143555A1
(fr)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Formulation d'arn pour immunothérapie
|
AU2013243946A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013162748A1
(fr)
|
2012-04-27 |
2013-10-31 |
The Trustees Of The University Of Pennsylvania |
Variants d'anticorps anti-marqueur 1 endothélial de tumeur (tem1) et leurs utilisations
|
KR102277921B1
(ko)
|
2012-05-21 |
2021-07-14 |
인스메드 인코포레이티드 |
폐 감염을 치료하기 위한 시스템
|
AR091143A1
(es)
|
2012-05-24 |
2015-01-14 |
Seeds Ltd Ab |
Composiciones y metodos para silenciar la expresion genetica
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
LT3489220T
(lt)
*
|
2012-06-08 |
2021-09-27 |
Nitto Denko Corporation |
Lipidai, skirti terapinėms agento pristatymo vaisto formoms
|
EP2859102A4
(fr)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
Polynucléotides résistant à la nucléase et leurs utilisations
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
TW201726599A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
JP6329537B2
(ja)
|
2012-07-11 |
2018-05-23 |
サンガモ セラピューティクス, インコーポレイテッド |
生物学的薬剤の送達のための方法および組成物
|
WO2014011237A1
(fr)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Méthodes et compositions pour le traitement de maladies lysosomales
|
CN104471062A
(zh)
|
2012-07-16 |
2015-03-25 |
协和发酵麒麟株式会社 |
抑制KRAS基因表达的RNAi医药组合物
|
CA2879683C
(fr)
|
2012-08-03 |
2023-02-14 |
Alnylam Pharmaceuticals, Inc. |
Agents constitues d'arni modifie
|
EP2698377A1
(fr)
|
2012-08-17 |
2014-02-19 |
Laboratorios Del. Dr. Esteve, S.A. |
Procédé de sélection rapide d'immunogène de variants de la GP-120 du VIH amélioré
|
KR102218562B1
(ko)
|
2012-08-29 |
2021-02-19 |
상가모 테라퓨틱스, 인코포레이티드 |
유전적 병태를 치료하기 위한 방법 및 조성물
|
WO2014035474A1
(fr)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions et méthodes de traitement du cancer
|
US9365856B2
(en)
|
2012-09-14 |
2016-06-14 |
The Board Of Trustees Of The University Of Arkansas |
Methods of using a serum response factor isoform
|
EP2943194A1
(fr)
|
2012-09-17 |
2015-11-18 |
Chemedest Ltd. |
Traitement d'une neuropathie périphérique à l'aide d'agonistes du récepteur de type 3 de gfr(alpha)3
|
TWI672149B
(zh)
|
2012-09-21 |
2019-09-21 |
美商Pds生技公司 |
改良之疫苗組成物及使用方法
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
EP2906602B1
(fr)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Protéines de fusion effecteur de type activateur de transcription (tale) - déméthylase 1 spécifique de la lysine (lsd1)
|
US10155031B2
(en)
|
2012-11-28 |
2018-12-18 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
CA2891487A1
(fr)
|
2012-11-29 |
2014-06-05 |
Insmed Incorporated |
Formulations de vancomycine stabilisees
|
HUE035887T2
(en)
|
2012-12-05 |
2018-05-28 |
Alnylam Pharmaceuticals Inc |
PCSK9 iRNA preparations and methods for their use
|
US10272163B2
(en)
|
2012-12-07 |
2019-04-30 |
The Regents Of The University Of California |
Factor VIII mutation repair and tolerance induction
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
WO2014093701A1
(fr)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications
|
JP6552965B2
(ja)
|
2012-12-12 |
2019-07-31 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
配列操作のための改善された系、方法および酵素組成物のエンジニアリングおよび最適化
|
US20140186843A1
(en)
|
2012-12-12 |
2014-07-03 |
Massachusetts Institute Of Technology |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
US20140189896A1
(en)
|
2012-12-12 |
2014-07-03 |
Feng Zhang |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
MX2015007549A
(es)
|
2012-12-12 |
2017-01-20 |
Broad Inst Inc |
Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
|
WO2014093694A1
(fr)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Systèmes, procédés et compositions de crispr-nickase cas pour la manipulation de séquences dans les eucaryotes
|
PL2931898T3
(pl)
|
2012-12-12 |
2016-09-30 |
Le Cong |
Projektowanie i optymalizacja systemów, sposoby i kompozycje do manipulacji sekwencją z domenami funkcjonalnymi
|
BR112015015976A2
(pt)
|
2013-01-01 |
2018-04-10 |
A. B. Seeds Ltd. |
método para introduzir dsrna em sementes para modular a expressão genética
|
US10683505B2
(en)
|
2013-01-01 |
2020-06-16 |
Monsanto Technology Llc |
Methods of introducing dsRNA to plant seeds for modulating gene expression
|
WO2014107739A1
(fr)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Anticorps dirigés contre pcsk9
|
EP3919505B1
(fr)
|
2013-01-16 |
2023-08-30 |
Emory University |
Utilisations des complexes d'acide nucléique cas9
|
WO2014124284A1
(fr)
|
2013-02-07 |
2014-08-14 |
The General Hospital Corporation |
Activateurs transcriptionnels tale
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
JP2016514091A
(ja)
|
2013-02-08 |
2016-05-19 |
ミスフォールディング ダイアグノスティクス, インコーポレイテッド |
トランスサイレチン抗体およびその使用
|
CA2901978A1
(fr)
|
2013-02-20 |
2014-08-28 |
Valerion Therapeutics, Llc |
Methodes et compositions pour le traitement de la maladie de pompe
|
CA2903716C
(fr)
|
2013-03-08 |
2019-04-09 |
Pfizer Inc. |
Polypeptides immunogenes de fusion
|
US10981961B2
(en)
|
2013-03-11 |
2021-04-20 |
University Of Florida Research Foundation, Incorporated |
Delivery of card protein as therapy for occular inflammation
|
ES2853935T3
(es)
|
2013-03-12 |
2021-09-20 |
Massachusetts Gen Hospital |
Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
|
EP3604535A3
(fr)
|
2013-03-13 |
2020-04-22 |
Monsanto Technology LLC |
Procédés et compositions utilisables pour lutter contre les mauvaises herbes
|
AU2014248958A1
(en)
|
2013-03-13 |
2015-10-01 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
CU24446B1
(es)
|
2013-03-13 |
2019-10-04 |
Prothena Biosciences Ltd |
Un anticuerpo monoclonal humanizado que se une a tau
|
WO2014139883A1
(fr)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Cibles et composés moléculaires, et méthodes utilisées pour les identifier, dans le cadre du traitement de la fibrose
|
US9957499B2
(en)
|
2013-03-14 |
2018-05-01 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
WO2014139884A2
(fr)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Cibles et composés moléculaires destinés au traitement de la fibrose, et méthodes utilisées pour les identifier
|
EP2971010B1
(fr)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
|
IL305374A
(en)
|
2013-03-14 |
2023-10-01 |
Ethris Gmbh |
CFTR mRNA Assemblies and Related Methods and Uses
|
US20160003808A1
(en)
|
2013-03-14 |
2016-01-07 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
|
MX366660B
(es)
|
2013-03-14 |
2019-07-18 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
|
CA2905649A1
(fr)
|
2013-03-15 |
2014-09-18 |
The Penn State Research Foundation |
Compositions et procedes comprenant du celecoxib et de la plombagine associes au traitement du cancer
|
AU2013381922A1
(en)
|
2013-03-15 |
2015-09-24 |
The Penn State Research Foundation |
Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
|
US10568328B2
(en)
|
2013-03-15 |
2020-02-25 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US9127024B2
(en)
|
2013-03-15 |
2015-09-08 |
Intrexon Corporation |
Boron-containing diacylhydrazines
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
WO2014145042A1
(fr)
|
2013-03-15 |
2014-09-18 |
Loma Linda University |
Traitement de maladies auto-immunes
|
WO2014180490A1
(fr)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Prédiction de l'immunogénicité d'épitopes de lymphocytes t
|
CN105683376A
(zh)
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
KR102234623B1
(ko)
|
2013-05-22 |
2021-04-02 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 조성물 및 이의 사용 방법
|
UY35582A
(es)
|
2013-05-22 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
|
EP3778899A1
(fr)
|
2013-05-22 |
2021-02-17 |
Northwestern University |
Clivage de l'adn orienté vers arn et édition génétique par l'enzyme cas9 provenant de neisseria meningitidis
|
WO2014193800A2
(fr)
|
2013-05-28 |
2014-12-04 |
The Johns Hopkins University |
Aptamères utiles dans le traitement de la drépanocytose
|
DK3007704T3
(da)
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
EP3011032B1
(fr)
|
2013-06-17 |
2019-10-16 |
The Broad Institute, Inc. |
Délivrance, modification et optimisation de systèmes, procédés et compositions pour cibler et modéliser des maladies et des troubles liés aux cellules post-mitotiques
|
WO2014204727A1
(fr)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Génomique fonctionnelle utilisant des systèmes crispr-cas, procédés de composition, cribles et applications de ces derniers
|
KR20160034901A
(ko)
|
2013-06-17 |
2016-03-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물
|
RU2716421C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
|
BR112015031608A2
(pt)
|
2013-06-17 |
2017-08-22 |
Massachusetts Inst Technology |
Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
WO2014210142A1
(fr)
|
2013-06-25 |
2014-12-31 |
Temple University-Of The Commonwealth System Of Higher Education |
Cellules souches dérivées d'os cortical
|
US9856472B2
(en)
|
2013-07-01 |
2018-01-02 |
California Institute Of Technology |
Small conditional RNAs
|
EP3608412A3
(fr)
|
2013-07-19 |
2020-04-08 |
Monsanto Technology LLC |
Compositions et méthodes de lutte contre leptinotarsa
|
US9850496B2
(en)
|
2013-07-19 |
2017-12-26 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
US20160151284A1
(en)
|
2013-07-23 |
2016-06-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
AU2014292926B2
(en)
|
2013-07-25 |
2020-03-05 |
Exicure Operating Company |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
WO2015023797A1
(fr)
*
|
2013-08-13 |
2015-02-19 |
Northwestern University |
Nanoparticules lipophiles pour l'administration de médicaments
|
JP6588438B2
(ja)
|
2013-08-28 |
2019-10-09 |
サンガモ セラピューティクス, インコーポレイテッド |
Dna結合ドメインと切断ドメインとを連結するための組成物
|
WO2015031645A1
(fr)
|
2013-08-28 |
2015-03-05 |
Washington University |
Anticorps monoclonaux anti-epsilon 14-3-3 humain et anti-sv epsilon 14-3-3 humain
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
EP3041935A1
(fr)
|
2013-09-05 |
2016-07-13 |
Sage Therapeutics, Inc. |
Inclusion de l'exon 2 induite par antisens dans une alpha-glucosidase acide
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
MX369534B
(es)
|
2013-09-08 |
2019-11-11 |
Pfizer |
Composiciones de neisseria meningitidis y sus metodos.
|
EP3047023B1
(fr)
|
2013-09-19 |
2019-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions et méthodes d'inhibition du virus jc (jcv)
|
AR097738A1
(es)
|
2013-09-23 |
2016-04-13 |
Alnylam Pharmaceuticals Inc |
Métodos para tratar o prevenir enfermedades asociadas con la transtiretina (ttr)
|
CA2925281C
(fr)
|
2013-09-25 |
2022-05-03 |
Zoetis Services Llc |
Composition vaccinale divergente anti-pcv2b et ses procedes d'utilisation
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
EP3574923A1
(fr)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Thérapie d'arnm pour phénylcétonurie
|
CA2928188A1
(fr)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Therapie arnm pour deficience en argininosuccinate synthetase
|
US9540642B2
(en)
|
2013-11-04 |
2017-01-10 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Compositions and methods for controlling arthropod parasite and pest infestations
|
US9487536B2
(en)
|
2013-11-08 |
2016-11-08 |
Board Of Trustees Of The University Of Arkansas |
Melampomagnolide B derivatives
|
US9469650B2
(en)
|
2013-11-08 |
2016-10-18 |
Board Of Trustees Of The University Of Arkansas |
Melampomagnolide B derivatives
|
NZ719477A
(en)
|
2013-11-11 |
2022-05-27 |
Sangamo Therapeutics Inc |
Methods and compositions for treating huntington’s disease
|
SI3068881T1
(sl)
|
2013-11-13 |
2019-05-31 |
Children's Medical Center Corporation |
Z nukleazo posredovano uravnavanje izražanja genov
|
CA2932122C
(fr)
|
2013-12-03 |
2022-04-19 |
Northwestern University |
Particules liposomales, leurs procedes de fabrication et leurs utilisations
|
KR20160110370A
(ko)
|
2013-12-04 |
2016-09-21 |
알엑스아이 파마슈티칼스 코포레이션 |
화학적으로 변형된 올리고뉴클레오티드를 사용한 상처 치유의 치료 방법
|
ES2813367T3
(es)
|
2013-12-09 |
2021-03-23 |
Sangamo Therapeutics Inc |
Métodos y composiciones para ingeniería genómica
|
UA119253C2
(uk)
|
2013-12-10 |
2019-05-27 |
Біолоджикс, Інк. |
Спосіб боротьби із вірусом у кліща varroa та у бджіл
|
AU2014362307A1
(en)
|
2013-12-11 |
2016-06-30 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
|
CA3107872A1
(fr)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Composition d'arni d'element de complement et procedes pour les utiliser
|
BR112016013201B1
(pt)
|
2013-12-12 |
2023-01-31 |
The Broad Institute, Inc. |
Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular
|
SG10201804975PA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
|
EP3079726B1
(fr)
|
2013-12-12 |
2018-12-05 |
The Broad Institute, Inc. |
Délivrance, utilisation et applications thérapeutiques des systèmes crispr-cas et compositions permettant de cibler des troubles et maladies au moyen de constituants de délivrance sous forme de particules
|
EP3080271B1
(fr)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systèmes, procédés et compositions pour manipulation de séquences avec systèmes crispr-cas fonctionnels optimisés
|
US10119136B2
(en)
|
2014-01-09 |
2018-11-06 |
Alnylam Pharmaceuticals, Inc. |
RNAi agents modified at the 4′-C position
|
WO2015108982A2
(fr)
|
2014-01-15 |
2015-07-23 |
Monsanto Technology Llc |
Procédés et compositions pour la lutte contre les mauvaises herbes utilisant des polynucléotides epsps
|
WO2015116902A1
(fr)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
Récepteurs couplés aux protéines g dans la signalisation hedgehog
|
PL3102673T3
(pl)
|
2014-02-03 |
2020-11-02 |
Sangamo Therapeutics, Inc. |
Sposoby i kompozycje do leczenia talasemii beta
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
EP3105331B1
(fr)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de cétohexokinase (khk) et procédés pour les utiliser
|
EP3107939B1
(fr)
|
2014-02-19 |
2020-06-17 |
University of Florida Research Foundation, Inc. |
Administration de nrf2 en tant que thérapie de protection contre les dérivés réactifs de l'oxygène
|
EP3110401A4
(fr)
|
2014-02-25 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Adjuvants de vaccins sous forme de nanoparticules lipidiques et systèmes d'administration d'antigènes
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
AU2015231353B2
(en)
|
2014-03-18 |
2020-11-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
WO2015153339A2
(fr)
|
2014-04-01 |
2015-10-08 |
Monsanto Technology Llc |
Compositions et procédés pour lutter contre les insectes nuisibles
|
ES2750661T3
(es)
|
2014-04-25 |
2020-03-26 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
EP3137119B1
(fr)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Procédés de traitement du cancer au moyen d'un acide nucléique ciblant mdm2
|
JP2017514908A
(ja)
|
2014-05-01 |
2017-06-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
核酸分子を利用する目の前部における障害の処置のための方法
|
EP3139942B1
(fr)
|
2014-05-05 |
2019-12-18 |
Bioventures, Llc |
Compositions et procédés d'inhibition de protéines antiapoptotiques bcl-2 comme agents anti-âge
|
WO2015171918A2
(fr)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions et leurs utilisations thérapeutiques
|
CN106413760B
(zh)
|
2014-05-08 |
2020-01-14 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿病的方法和组合物
|
PL3142643T3
(pl)
|
2014-05-15 |
2019-12-31 |
Insmed Incorporated |
Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
US10066241B2
(en)
|
2014-05-30 |
2018-09-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
PL3164113T3
(pl)
|
2014-06-04 |
2019-09-30 |
Exicure, Inc. |
Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
|
CN106852157B
(zh)
|
2014-06-16 |
2022-04-12 |
约翰斯·霍普金斯大学 |
用于使用h1启动子表达crispr向导rna的组合物和方法
|
CN106795515B
(zh)
|
2014-06-23 |
2021-06-08 |
孟山都技术公司 |
用于经由rna干扰调控基因表达的组合物和方法
|
EP3161138A4
(fr)
|
2014-06-25 |
2017-12-06 |
Monsanto Technology LLC |
Procédés et compositions pour administrer des acides nucléiques à des cellules végétales et réguler l'expression génique
|
CA2985344A1
(fr)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
L'inhibition de l'expression de la serotonine dans des cellules enteroendocrines intestinales provoque leur conversion en cellules positives pour l'insuline
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
EP3169310A1
(fr)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules
|
US10071087B2
(en)
|
2014-07-22 |
2018-09-11 |
Bioventures, Llc |
Compositions and methods for selectively depleting senescent cells
|
US10449261B2
(en)
|
2014-07-24 |
2019-10-22 |
Washington University |
Compositions targeting radiation-induced molecules and methods of use thereof
|
KR102330593B1
(ko)
|
2014-07-28 |
2021-11-26 |
에스케이이노베이션 주식회사 |
신규 이소프렌 신타아제 및 이를 이용한 이소프렌의 제조방법
|
UA125244C2
(uk)
|
2014-07-29 |
2022-02-09 |
Монсанто Текнолоджі Елелсі |
Спосіб умертвіння або припинення росту комахи
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
EP3686279B1
(fr)
|
2014-08-17 |
2023-01-04 |
The Broad Institute, Inc. |
Édition du génome à l'aide de nickases cas9
|
CN114181942A
(zh)
|
2014-08-20 |
2022-03-15 |
阿尔尼拉姆医药品有限公司 |
经修饰的双链rna试剂
|
WO2016033424A1
(fr)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Méthodes de prévention et de traitement d'évènements indésirables cardiovasculaires majeurs à l'aide de composés modulant l'apolipoprotéine b
|
US10900039B2
(en)
|
2014-09-05 |
2021-01-26 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
|
BR112017004893A2
(pt)
|
2014-09-10 |
2017-12-12 |
Univ Washington |
composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
|
EP3191591A1
(fr)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Agents polynucléotidiques ciblant le composant du complément c5 et leurs méthodes d'utilisation
|
WO2016044416A1
(fr)
|
2014-09-16 |
2016-03-24 |
Sangamo Biosciences, Inc. |
Procédés et compositions pour ingénierie génomique à médiation par des nucléases et correction du génome dans des cellules souches hématopoïétiques
|
US9944659B2
(en)
|
2014-09-17 |
2018-04-17 |
Intrexon Corporation |
Boron-containing diacylhydrazine compounds
|
WO2016049251A1
(fr)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Administration, utilisation et applications thérapeutiques de systèmes crispr-cas et compositions de modélisation de mutations dans des leucocytes
|
WO2016049163A2
(fr)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Utilisation et production d'animaux transgéniques chd8 +/- possédant des phénotypes de comportement caractéristiques d'un trouble du spectre autistique
|
WO2016049024A2
(fr)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Administration, utilisation et applications thérapeutiques des systèmes crispr-cas et compositions permettant de modéliser la concurrence de multiples mutations cancéreuses in vivo
|
WO2016045732A1
(fr)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Formulations stables de lipides et de liposomes
|
AU2015328012A1
(en)
|
2014-10-02 |
2017-05-11 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing Hepatitis B virus gene expression
|
KR20170063949A
(ko)
|
2014-10-06 |
2017-06-08 |
엑시큐어, 인크. |
항-tnf 화합물
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(fr)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Agents polynucléotidiques de ciblage d'acide aminolévulinique synthase-1 (alas1) et utilisations de ceux-ci
|
US10918629B2
(en)
|
2014-10-20 |
2021-02-16 |
The Curators Of The University Of Missouri |
Method for treating lymphedema
|
EP3212794B1
(fr)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Agents polynucléotidiques ciblant serpinc 1 (at3) et leurs méthodes d'utilisation
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法
|
EP3226889A4
(fr)
|
2014-11-19 |
2018-11-21 |
The Trustees of Columbia University in the City of New York |
Ostéocalcine comme traitement de fragilité associée au vieillissement
|
US10517924B2
(en)
|
2014-11-24 |
2019-12-31 |
Northwestern University |
High density lipoprotein nanoparticles for inflammation
|
US9981990B2
(en)
|
2014-12-03 |
2018-05-29 |
Bioventures, Llc |
Melampomagnolide B dimers
|
WO2016093205A1
(fr)
*
|
2014-12-08 |
2016-06-16 |
日油株式会社 |
Procédé de production de lipide cationique
|
WO2016094874A1
(fr)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Guides escortés et fonctionnalisés pour systèmes crispr-cas
|
EP3230452A1
(fr)
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Guides désactivés pour facteurs de transcription crispr
|
EP3985115A1
(fr)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Arn guides protégés (pgrnas)
|
ES2881374T3
(es)
|
2014-12-15 |
2021-11-29 |
Univ Washington |
Composiciones y procedimientos para la administración direccionada de citoquinas
|
WO2016106236A1
(fr)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Système de ciblage d'arn
|
EP3702456A1
(fr)
|
2014-12-24 |
2020-09-02 |
The Broad Institute, Inc. |
Crispr présentant ou associé à un domaine de déstabilisation
|
WO2016108926A1
(fr)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Modélisation et dépistage génétique in vivo, médiés par crispr, de la croissance tumorale et de métastases
|
PL3256589T3
(pl)
|
2015-01-22 |
2022-02-21 |
Monsanto Technology Llc |
Kompozycje i sposoby kontrolowania leptinotarsa
|
LT3250691T
(lt)
|
2015-01-28 |
2023-09-11 |
Caribou Biosciences, Inc. |
Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai
|
WO2016128060A1
(fr)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Prédiction des épitopes de lymphocytes t utiles pour la vaccination
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
RU2723045C2
(ru)
|
2015-02-19 |
2020-06-08 |
Пфайзер Инк. |
Композиции neisseria meningitidis и способы их получения
|
EP3265063A4
(fr)
*
|
2015-03-03 |
2018-11-07 |
Cureport, Inc. |
Formulations pharmaceutiques liposomales à double charge
|
EP3265059A4
(fr)
|
2015-03-03 |
2018-08-29 |
Cureport Inc. |
Formulations pharmaceutiques liposomales en combinaison
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
EP3069730A3
(fr)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
|
EP3072901A1
(fr)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
|
ES2959608T3
(es)
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composición y métodos de edición del genoma de células B
|
WO2016164746A1
(fr)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions et méthodes d'inhibition de l'expression du gène lect2
|
WO2016168601A1
(fr)
|
2015-04-17 |
2016-10-20 |
Khalid Shah |
Agents, systèmes et méthodes de traitement du cancer
|
SI3288379T1
(sl)
|
2015-05-01 |
2022-06-30 |
Onl Therapeutics, Inc. |
Peptidne sestave in načini uporabe
|
CN108271386B
(zh)
|
2015-05-06 |
2022-07-15 |
阿尔尼拉姆医药品有限公司 |
因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法
|
CA2986021A1
(fr)
|
2015-05-16 |
2016-11-24 |
Genzyme Corporation |
Edition genique de mutations introniques profondes
|
WO2016187499A1
(fr)
|
2015-05-20 |
2016-11-24 |
Syracuse University |
Régulation glycémique améliorée à l'aide d'un facteur intrinsèque lié à un conjugué de vitamine b12 d'un agoniste du récepteur du glucagon-like peptide-1
|
US10716827B2
(en)
|
2015-05-20 |
2020-07-21 |
Syracuse University |
Compositions and methods for enhancing peptide stability against protease digestion
|
EP3303586A1
(fr)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
EP3851531A1
(fr)
|
2015-06-01 |
2021-07-21 |
Sarepta Therapeutics, Inc. |
Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
|
EP3302053B1
(fr)
|
2015-06-02 |
2021-03-17 |
Monsanto Technology LLC |
Compositions et procédés pour l'administration d'un polynucléotide dans une plante
|
AU2016270913A1
(en)
|
2015-06-03 |
2018-01-04 |
Monsanto Technology Llc |
Methods and compositions for introducing nucleic acids into plants
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
TW201710503A
(zh)
|
2015-06-12 |
2017-03-16 |
長庚醫療財團法人林口長庚紀念醫院 |
新穎多核苷酸、載體、醫藥組成物以及其用途
|
EP3307316A1
(fr)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation
|
WO2016205728A1
(fr)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Enregistrement d'événements cellulaires médié par crispr
|
AU2016279077A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
EP3436575A1
(fr)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Nouvelles enzymes crispr et systèmes associés
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
EP3310918B1
(fr)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Agents polynucléotidiques ciblant l'hydroxyacide oxydase (glycolate oxydase, hao1) et procédés d'utilisation de ceux-ci
|
WO2016209862A1
(fr)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arndb contre un gène de glucokinase (gck) et leurs procédés d'utilisation
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
US11001845B2
(en)
|
2015-07-06 |
2021-05-11 |
Phio Pharmaceuticals Corp. |
Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
EP3322297A4
(fr)
|
2015-07-13 |
2019-04-17 |
Sangamo Therapeutics, Inc. |
Procédés d'administration et compositions pour génie génomique médié par nucléase
|
WO2017011728A1
(fr)
|
2015-07-15 |
2017-01-19 |
Washington University |
Anticorps contre des tumeurs associées à des n-glycanes complexes avec des résidus glcnabêta terminaux et procédés pour les utiliser
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
WO2017019891A2
(fr)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
|
WO2017024317A2
(fr)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles
|
CA2995995A1
(fr)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Nanoparticules polynucleotidiques pour la modulation de l'expression genique et leurs utilisations
|
JP6929272B2
(ja)
|
2015-08-28 |
2021-09-01 |
セルピン ファーマ リミテッド ライアビリティ カンパニー |
疾患処置のための方法
|
PE20181131A1
(es)
|
2015-09-02 |
2018-07-17 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
|
WO2017048620A1
(fr)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Agents de polynucléotide ciblant un domaine de phospholipase de type patatine contenant 3 (pnpla3) et leurs procédés d'utilisation
|
EP3352800B1
(fr)
|
2015-09-24 |
2022-01-05 |
The University of North Carolina at Chapel Hill |
Méthodes et compositions pour réduire les métastases
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
WO2017059902A1
(fr)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
Séquences utr 3' permettant la stabilisation d'arn
|
EP3359668A4
(fr)
|
2015-10-09 |
2019-06-05 |
Sarepta Therapeutics, Inc. |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
CA3000917A1
(fr)
|
2015-10-09 |
2017-04-13 |
Monsanto Technology Llc |
Nucleases guidees par arn et leurs utilisations
|
AU2016334401A1
(en)
|
2015-10-10 |
2018-04-26 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
RU2732567C2
(ru)
|
2015-10-16 |
2020-09-21 |
Ипсен Биофарм Лтд. |
Стабилизированные фармацевтические композиции камптотецина
|
CA3002744A1
(fr)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Composes d'acides nucleiques de taille reduite a auto-administration ciblant des longs arn non codants
|
EP3365441A1
(fr)
|
2015-10-22 |
2018-08-29 |
The Broad Institute Inc. |
Enzymes et systèmes crispr de type vi-b
|
IL310721A
(en)
|
2015-10-23 |
2024-04-01 |
Harvard College |
Nucleobase editors and their uses
|
WO2017079429A1
(fr)
|
2015-11-05 |
2017-05-11 |
Board Of Trustees Of The University Of Arkansas |
Analogues de lactone cycliques à substitution hétéro et utilisations associés
|
CA3007424A1
(fr)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
Mobilisation de cellules leucemiques
|
WO2017083820A1
(fr)
|
2015-11-13 |
2017-05-18 |
Pds Biotechnology Corporation |
Lipides en tant que vecteurs synthétiques pour améliorer le traitement et la présentation de l'antigène ex-vivo en thérapie cellulaire dendritique
|
CA3006779A1
(fr)
|
2015-12-09 |
2017-06-15 |
Admedus Vaccines Pty Ltd |
Composition immunomodulatrice pour le traitement
|
WO2017100542A1
(fr)
|
2015-12-10 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni chaperon (scap) de la protéine srebp (sterol regulatory element binding protein), et procédés d'utilisation associés
|
BR112018012235A2
(pt)
|
2015-12-18 |
2018-12-04 |
Sangamo Therapeutics Inc |
rompimento alvejado do receptor de células de mhc
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
CA3009131A1
(fr)
|
2015-12-25 |
2017-06-29 |
Kyowa Hakko Kirin Co., Ltd. |
Composes comme lipides cationiques et utilisation dans les compositions d'administration d'acide nucleique
|
WO2017120589A1
(fr)
|
2016-01-08 |
2017-07-13 |
Washington University |
Compositions comprenant de la chémérine et méthodes pour les utiliser
|
AU2017207818B2
(en)
|
2016-01-15 |
2024-03-28 |
Regents Of The University Of Minnesota |
Methods and compositions for the treatment of neurologic disease
|
WO2017132528A1
(fr)
|
2016-01-29 |
2017-08-03 |
Bioventures, Llc |
Dérivés de triazole de melampomagnolide b et leurs procédés d'utilisation
|
EP3769775A3
(fr)
|
2016-02-02 |
2021-03-17 |
Sangamo Therapeutics, Inc. |
Compositions pour lier des domaines de liaison à l'adn et des domaines de clivage
|
CA3019952A1
(fr)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened et methodes d'utilisation dudit mutant
|
CN109071679B
(zh)
|
2016-02-05 |
2023-07-28 |
华盛顿大学 |
用于靶向的细胞因子递送的组合物和方法
|
WO2017147056A1
(fr)
|
2016-02-22 |
2017-08-31 |
Caribou Biosciences, Inc. |
Méthodes de modulation de résultats de réparation d'adn
|
GB201604235D0
(en)
|
2016-03-11 |
2016-04-27 |
Ucl Business Plc |
Lipids and complexes for the delivery of biologically-active material to cells
|
AU2017237163B2
(en)
|
2016-03-24 |
2021-07-29 |
Marquette University |
Quantitative flagellar fluorescent markers and standards
|
US10213448B2
(en)
|
2016-03-25 |
2019-02-26 |
Novazoi Theranostics |
Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
|
WO2017184529A1
(fr)
|
2016-04-18 |
2017-10-26 |
Sarepta Therapeutics, Inc. |
Oligomères antisens et procédés d'utilisation de ceux-ci pour le traitement de maladies associées au gène de l'alpha-glucosidase acide
|
WO2017189308A1
(fr)
|
2016-04-19 |
2017-11-02 |
The Broad Institute Inc. |
Nouvelles enzymes crispr et systèmes associés
|
WO2017184786A1
(fr)
|
2016-04-19 |
2017-10-26 |
The Broad Institute Inc. |
Complexes cpf1 à activité d'indel réduite
|
CN110382692A
(zh)
|
2016-04-19 |
2019-10-25 |
博德研究所 |
新型crispr酶以及系统
|
KR102447884B1
(ko)
|
2016-04-21 |
2022-09-27 |
바이오벤처스, 엘엘씨 |
항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
|
CN109415432B
(zh)
|
2016-05-02 |
2022-07-08 |
普罗塞纳生物科学有限公司 |
Tau免疫疗法
|
CA3022765A1
(fr)
|
2016-05-02 |
2017-11-09 |
Prothena Biosciences Limited |
Anticorps reconnaissant la proteine tau
|
EP3452508A1
(fr)
|
2016-05-02 |
2019-03-13 |
Prothena Biosciences Limited |
Anticorps reconnaissant tau
|
JP7186094B2
(ja)
|
2016-05-06 |
2022-12-08 |
イグジキュア オペレーティング カンパニー |
インターロイキン17受容体mRNAの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド(ASO)を提示するリポソーム系球状核酸(SNA)構築物
|
EP3469083A1
(fr)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni du composant c5 du complément et leurs méthodes d'utilisation pour traiter l'hémoglobinurie paroxystique nocturne (hpn)
|
EP3472329A1
(fr)
|
2016-06-16 |
2019-04-24 |
Oslo Universitetssykehus HF |
Édition de gène améliorée
|
JP7267013B2
(ja)
|
2016-06-17 |
2023-05-01 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Vi型crisprオルソログ及び系
|
US20210222164A1
(en)
|
2016-06-29 |
2021-07-22 |
The Broad Institute, Inc. |
Crispr-cas systems having destabilization domain
|
US11191849B2
(en)
|
2016-06-30 |
2021-12-07 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
ES2908919T3
(es)
|
2016-07-05 |
2022-05-04 |
California Inst Of Techn |
Reacción en cadena de hibridación de iniciador fraccionario
|
US11766488B2
(en)
|
2016-07-05 |
2023-09-26 |
The Johns Hopkins University |
Compositions and methods comprising improvements of CRISPR guide RNAS using the H1 promoter
|
EP3484870B1
(fr)
|
2016-07-13 |
2022-11-16 |
Vertex Pharmaceuticals Incorporated |
Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
|
US11674158B2
(en)
|
2016-07-15 |
2023-06-13 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
CA2937157A1
(fr)
|
2016-07-25 |
2018-01-25 |
Ucl Business Plc |
Ecrasement de recepteur de cellule t fonde sur une proteine
|
CA3032699A1
(fr)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harvard College |
Editeurs de nucleobases d'adenosine et utilisations associees
|
JP2019528312A
(ja)
|
2016-08-07 |
2019-10-10 |
ノバルティス アーゲー |
mRNA媒介性の免疫化方法
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
WO2018039438A1
(fr)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
|
CN110325635B
(zh)
|
2016-08-24 |
2023-12-26 |
桑格摩生物治疗股份有限公司 |
使用工程化的核酸酶调控基因表达
|
KR102455249B1
(ko)
|
2016-08-24 |
2022-10-17 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
CA3034617A1
(fr)
|
2016-08-30 |
2018-03-08 |
California Institute Of Technology |
Immunohistochimie par reaction en chaine d'hybridation
|
EP3519578B1
(fr)
*
|
2016-10-03 |
2021-12-22 |
Precision Nanosystems Inc |
Compositions pour la transfection de types de cellules résistantes
|
CN110050061A
(zh)
|
2016-10-05 |
2019-07-23 |
富士胶片细胞动力公司 |
从具有MeCP2破坏的诱导多能干细胞生成成熟谱系
|
EP4190335A1
(fr)
|
2016-10-13 |
2023-06-07 |
Juno Therapeutics, Inc. |
Procédés et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
|
CN110214180A
(zh)
|
2016-10-14 |
2019-09-06 |
哈佛大学的校长及成员们 |
核碱基编辑器的aav递送
|
MX2019004487A
(es)
|
2016-10-20 |
2020-02-07 |
Sangamo Therapeutics Inc |
Metodos y composiciones para el tratamiento de la enfermedad de fabry.
|
WO2018075592A1
(fr)
|
2016-10-21 |
2018-04-26 |
Merck Sharp & Dohme Corp. |
Vaccins contre la grippe à base de protéine hémagglutinine
|
WO2018081388A1
(fr)
|
2016-10-26 |
2018-05-03 |
Washington University |
Compositions comprenant de la desaminotyrosine et leurs utilisations pour améliorer la stimulation de l'interféron de type i
|
US11020492B2
(en)
|
2016-10-31 |
2021-06-01 |
Sangamo Therapeutics, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
US10011848B2
(en)
|
2016-11-09 |
2018-07-03 |
City University Of Hong Kong |
System and method for delivery of substance into mammalian cells
|
US11116852B2
(en)
|
2016-11-09 |
2021-09-14 |
Precigen, Inc. |
Frataxin expression constructs
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
US11793833B2
(en)
|
2016-12-02 |
2023-10-24 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
ES2968892T3
(es)
|
2016-12-08 |
2024-05-14 |
Univ Case Western Reserve |
Métodos y composiciones para aumentar la producción de mielina funcional
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
US20230193321A1
(en)
|
2016-12-20 |
2023-06-22 |
Bristol-Myers Squibb Company |
Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
|
WO2018119359A1
(fr)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
|
JP7010961B2
(ja)
|
2017-01-31 |
2022-02-10 |
ファイザー・インク |
髄膜炎菌組成物およびその方法
|
US11352436B2
(en)
|
2017-02-10 |
2022-06-07 |
Washington University |
Antibodies to TIP1 and methods of use thereof
|
EP3585417B1
(fr)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Méthode de préparation d'arnm cftr à codons optimisés
|
EP3592853A1
(fr)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression de la douleur par édition de gène
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
WO2018170333A1
(fr)
|
2017-03-15 |
2018-09-20 |
The Broad Institute, Inc. |
Nouvelles enzymes crispr orthologues cas13b et systèmes
|
CN110914426A
(zh)
|
2017-03-23 |
2020-03-24 |
哈佛大学的校长及成员们 |
包含核酸可编程dna结合蛋白的核碱基编辑器
|
EP3526324B1
(fr)
|
2017-03-28 |
2021-08-25 |
Locanabio, Inc. |
Protéine associée à crispr (cas)
|
EP3610009A1
(fr)
|
2017-04-12 |
2020-02-19 |
The Broad Institute, Inc. |
Nouveaux orthologues de crispr de type vi et systèmes associés
|
MA50278A
(fr)
|
2017-04-18 |
2020-02-26 |
Alnylam Pharmaceuticals Inc |
Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
|
WO2018201088A1
(fr)
|
2017-04-27 |
2018-11-01 |
Washington University |
Activation du récepteur 2 de la cytotoxicité naturelle (ncr2)
|
US11351227B2
(en)
|
2017-04-27 |
2022-06-07 |
Washington University |
Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
|
US11696954B2
(en)
|
2017-04-28 |
2023-07-11 |
Exicure Operating Company |
Synthesis of spherical nucleic acids using lipophilic moieties
|
KR20200030029A
(ko)
|
2017-05-02 |
2020-03-19 |
프로테나 바이오사이언시즈 리미티드 |
타우 인식 항체
|
US20210278416A1
(en)
|
2017-05-09 |
2021-09-09 |
The Broad Institute, Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
CN110621688A
(zh)
|
2017-05-09 |
2019-12-27 |
非营利性组织佛兰芒综合大学生物技术研究所 |
用于治疗细菌感染的手段和方法
|
WO2018209320A1
(fr)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
|
CA3067164A1
(fr)
|
2017-06-12 |
2018-12-20 |
Washington University |
Souches du virus zika pour le traitement du glioblastome
|
KR20200027512A
(ko)
|
2017-06-20 |
2020-03-12 |
엥스띠뛰 퀴리 |
Suv39h1에 결함이 있는 면역 세포
|
AU2018289077B2
(en)
|
2017-06-23 |
2022-03-10 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
JP7454494B2
(ja)
|
2017-06-26 |
2024-03-22 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
標的化された核酸編集のためのcrispr/cas-アデニンデアミナーゼ系の組成物、系及び方法
|
MX2020000387A
(es)
|
2017-07-13 |
2020-08-17 |
Univ Northwestern |
Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
EP3661506A4
(fr)
|
2017-07-31 |
2021-04-21 |
Washington University |
Dérivés de la pirfénidone pour la modulation de l'activité des lymphocytes b et la protection des organes
|
EP3668497A4
(fr)
|
2017-08-14 |
2021-04-28 |
Washington University |
Procédés et compositions de traitement de maladies associées au cancer, à une inflammation ou à une réponse immunitaire
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
US11097018B2
(en)
|
2017-09-06 |
2021-08-24 |
Washington University |
Organomedicinals for imaging and treatment of neurodegenerative disorders
|
CN111511388A
(zh)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
用于靶向核酸编辑的系统、方法和组合物
|
AU2018352592A1
(en)
|
2017-10-16 |
2020-06-04 |
Beam Therapeutics, Inc. |
Uses of adenosine base editors
|
WO2019079637A2
(fr)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
Composés oligomères antisens
|
WO2019089982A1
(fr)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Procédé d'évaluation de l'activité de récepteurs antigéniques de recombinaison
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
CN107827762B
(zh)
*
|
2017-11-14 |
2020-10-02 |
苏州东南药业股份有限公司 |
一种(2,3-二油酰基-丙基)三甲基氯化铵及其制备方法和用途
|
AU2018368786A1
(en)
|
2017-11-17 |
2020-06-18 |
Iovance Biotherapeutics, Inc. |
TIL expansion from fine needle aspirates and small biopsies
|
WO2019100039A1
(fr)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de composant p amyloïde serique et leurs procédés d'utilisation
|
CA3083118A1
(fr)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion de lymphocytes de sang peripherique (pbl) a partir de sang peripherique
|
TW201936201A
(zh)
|
2017-12-14 |
2019-09-16 |
美商堅固生物科技公司 |
基因之非病毒生產及遞送
|
EP3728281A1
(fr)
|
2017-12-21 |
2020-10-28 |
Alnylam Pharmaceuticals Inc. |
Agents d'arn double brin à enrichissement chiral
|
WO2019136456A1
(fr)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral
|
WO2019136459A1
(fr)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
EP3740479A1
(fr)
|
2018-01-17 |
2020-11-25 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs d'adn-pk
|
EA202091707A1
(ru)
|
2018-01-17 |
2020-12-02 |
Вертекс Фармасьютикалз Инкорпорейтед |
Хиноксалиноновые соединения, композиции, способы и наборы для повышения эффективности редактирования генома
|
CN111757876B
(zh)
|
2018-01-17 |
2024-03-22 |
沃泰克斯药物股份有限公司 |
Dna-pk抑制剂
|
CA3088253A1
(fr)
|
2018-01-22 |
2019-07-25 |
Bioventures, Llc |
Agents de degradation de proteines bcl-2 pour le traitement du cancer
|
JP2021511356A
(ja)
|
2018-01-29 |
2021-05-06 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
安定化rsv fタンパク質およびその使用
|
CN108129338A
(zh)
*
|
2018-02-01 |
2018-06-08 |
爱斯特(成都)生物制药股份有限公司 |
一种阳性脂质体dotap的制备方法
|
WO2019160383A1
(fr)
|
2018-02-19 |
2019-08-22 |
고려대학교 산학협력단 |
Vaccin comprenant un épitope de protéine de choc thermique et utilisation associée
|
EP3539975A1
(fr)
|
2018-03-15 |
2019-09-18 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Micropeptides et leurs utilisations
|
WO2019191627A1
(fr)
|
2018-03-30 |
2019-10-03 |
Insmed Incorporated |
Procédés pour la fabrication continue de produits médicamenteux liposomaux
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
EP3797160A1
(fr)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Éditeurs de bases et leurs utilisations
|
KR20210089629A
(ko)
|
2018-06-05 |
2021-07-16 |
라이프에디트 테라퓨틱스, 인크. |
Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법
|
CA3106035A1
(fr)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Enzymes cas12b et systemes
|
JP2021534101A
(ja)
|
2018-08-09 |
2021-12-09 |
ヴェルソー セラピューティクス, インコーポレイテッド |
Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用
|
EP3835320A4
(fr)
|
2018-08-10 |
2022-06-01 |
Eutilex Co., Ltd. |
Liaison du récepteur antigénique chimérique à hla-dr, et cellule car-t
|
WO2020041380A1
(fr)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Méthodes et compositions de régulation optochimique de crispr-cas9
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
CA3105385A1
(fr)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de cetohexokinase (khk) et leurs procedes d'utilisation
|
CN113015741A
(zh)
|
2018-09-18 |
2021-06-22 |
桑格摩生物治疗股份有限公司 |
程序性细胞死亡1(pd1)特异性核酸酶
|
WO2020069029A1
(fr)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Nouvelles nucléases crispr
|
GB201815820D0
(en)
|
2018-09-28 |
2018-11-14 |
Univ Wageningen |
Off-target activity inhibitors for guided endonucleases
|
MX2021003663A
(es)
|
2018-09-28 |
2021-05-28 |
Harvard College |
Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos.
|
WO2020079033A1
(fr)
|
2018-10-15 |
2020-04-23 |
Fondazione Telethon |
Procédés et constructions d'édition de génome
|
WO2020092453A1
(fr)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Éditeurs de nucléobases comprenant geocas9 et utilisations associées
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
AU2019377422A1
(en)
|
2018-11-05 |
2021-05-27 |
Iovance Biotherapeutics, Inc. |
Treatment of NSCLC patients refractory for anti-PD-1 antibody
|
TW202039830A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
|
US20220033775A1
(en)
|
2018-11-05 |
2022-02-03 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathways inhibitors
|
US20230039976A1
(en)
|
2018-11-05 |
2023-02-09 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
US20220282275A1
(en)
|
2018-11-15 |
2022-09-08 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
US20220056444A1
(en)
|
2018-12-05 |
2022-02-24 |
Empirico Inc. |
Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
|
EP3898958A1
(fr)
|
2018-12-17 |
2021-10-27 |
The Broad Institute, Inc. |
Systèmes de transposases associés à crispr et procédés d'utilisation correspondants
|
WO2020131547A1
(fr)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Procédés pour la multiplication de lymphocytes infiltrant les tumeurs à l'aide de paires de récepteurs de cytokines modifiés et leurs utilisations
|
EP3898977A1
(fr)
|
2018-12-20 |
2021-10-27 |
Praxis Precision Medicines, Inc. |
Compositions et méthodes pour le traitement des maladies associés à kcnt1
|
ES2970169T3
(es)
|
2018-12-27 |
2024-05-27 |
Lifeedit Therapeutics Inc |
Polipéptidos útiles para edición génica y métodos de uso
|
US11116778B2
(en)
|
2019-01-15 |
2021-09-14 |
Empirico Inc. |
Prodrugs of ALOX-15 inhibitors and methods of using the same
|
US20220098621A1
(en)
|
2019-02-05 |
2022-03-31 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
WO2020163307A1
(fr)
|
2019-02-06 |
2020-08-13 |
Emendobio Inc. |
Nouvelle cas9 haute fidélité modifiée
|
WO2020163017A1
(fr)
|
2019-02-06 |
2020-08-13 |
Klogenix Llc |
Protéines de liaison à l'adn et leurs utilisations
|
WO2020172343A2
(fr)
|
2019-02-19 |
2020-08-27 |
Massachusetts Institute Of Technology |
Méthodes de traitement de lésions
|
MX2021010288A
(es)
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
PE20212324A1
(es)
|
2019-03-03 |
2021-12-14 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
WO2020181193A1
(fr)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
Édition de bases t:a à a:t par méthylation de l'adénosine
|
WO2020181195A1
(fr)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
Édition de base t : a à a : t par excision d'adénine
|
WO2020181202A1
(fr)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
Édition de base a:t en t:a par déamination et oxydation d'adénine
|
WO2020181178A1
(fr)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
Édition de base t:a à a:t par alkylation de thymine
|
WO2020181180A1
(fr)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
Éditeurs de base a:t en c:g et leurs utilisations
|
WO2020185628A1
(fr)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Compositions de cd40l et procédés de régulation accordable
|
GB201903499D0
(en)
|
2019-03-14 |
2019-05-01 |
Ucl Business Plc |
Minimal promoter
|
WO2020191102A1
(fr)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Systèmes et protéines crispr de type vii
|
AU2020242032A1
(en)
|
2019-03-19 |
2021-10-07 |
Massachusetts Institute Of Technology |
Methods and compositions for editing nucleotide sequences
|
MA55531A
(fr)
|
2019-04-02 |
2022-02-09 |
Sangamo Therapeutics Inc |
Procédés pour le traitement de béta-thalassémie
|
US11964001B2
(en)
|
2019-04-09 |
2024-04-23 |
Washington University |
Compositions for treating or preventing respiratory tract infections and method of use thereof
|
EP3953461A4
(fr)
|
2019-04-09 |
2023-05-31 |
The Regents of The University of California |
Analgésie longue durée par répression épigénétique ciblée in vivo
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
EP3956349A1
(fr)
|
2019-04-17 |
2022-02-23 |
The Broad Institute, Inc. |
Éditeurs de base d'adénine présentant des effets hors cible réduits
|
US20220175723A1
(en)
|
2019-04-22 |
2022-06-09 |
The Penn State Research Foundation |
Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer
|
WO2020223539A1
(fr)
|
2019-04-30 |
2020-11-05 |
The Broad Institute, Inc. |
Procédés et compositions permettant de marquer des banques d'acide nucléique et des populations cellulaires avec un code-barres
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
US20220249701A1
(en)
|
2019-05-14 |
2022-08-11 |
The Broad Institute, Inc. |
Compositions and methods for targeting multinucleated cells
|
CA3138915A1
(fr)
|
2019-05-17 |
2020-11-26 |
Alnylam Pharmaceuticals, Inc. |
Administration orale d'oligonucleotides
|
WO2020236972A2
(fr)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Systèmes de ciblage d'acides nucléiques à constituants multiples autres que de classe i
|
EP3973054A1
(fr)
|
2019-05-20 |
2022-03-30 |
The Broad Institute Inc. |
Administration d'aav d'éditeurs de nucléobases
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
US20210317192A9
(en)
|
2019-05-29 |
2021-10-14 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
EP4166671A1
(fr)
|
2019-05-29 |
2023-04-19 |
Altria Client Services LLC |
Compositions et procédés de production de plants de tabac et de produits ayant des drageons réduits ou éliminés
|
GB201909597D0
(en)
|
2019-07-03 |
2019-08-14 |
Univ Wageningen |
Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof
|
MX2022000922A
(es)
|
2019-07-23 |
2022-05-03 |
Mnemo Therapeutics |
Celulas inmunes defectuosas para suv39h1.
|
WO2021025750A1
(fr)
|
2019-08-08 |
2021-02-11 |
The Broad Institute, Inc. |
Éditeurs de bases à portée de ciblage diversifiée
|
KR20220062289A
(ko)
|
2019-08-12 |
2022-05-16 |
라이프에디트 테라퓨틱스, 인크. |
Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법
|
WO2021030522A1
(fr)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'agent d'arni à sous-unité de protéine ribosomale 25 (rps25) et leurs procédés d'utilisation
|
WO2021030666A1
(fr)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Édition de bases par transglycosylation
|
AU2020333667A1
(en)
|
2019-08-16 |
2022-02-24 |
Massachusetts Institute Of Technology |
Targeted trans-splicing using CRISPR/Cas13
|
KR102099342B1
(ko)
|
2019-09-03 |
2020-04-10 |
주식회사 제노포커스 |
Crm197 단백질 발현 방법
|
WO2021072328A1
(fr)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Procédés et compositions pour le prime editing d'arn
|
EP4040947A2
(fr)
|
2019-10-10 |
2022-08-17 |
Altria Client Services LLC |
Locus jaune pâle et ses applications dans le tabac
|
JP2022553828A
(ja)
|
2019-11-01 |
2022-12-26 |
サンガモ セラピューティクス, インコーポレイテッド |
ゲノム操作のための組成物および方法
|
TW202132567A
(zh)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
|
WO2021092464A2
(fr)
|
2019-11-08 |
2021-05-14 |
Phio Pharmaceuticals Corp. |
Oligonucléotides chimiquement modifiés ciblant la protéine à bromodomaine 4 (brd4) pour immunothérapie
|
WO2021102373A1
(fr)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'agent arni d'ataxine 3 (atxn3) et leurs procédés d'utilisation
|
WO2021108717A2
(fr)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systèmes et procédés pour l'évaluation d'édition hors cible indépendante de cas9 d'acides nucléiques
|
WO2021118990A1
(fr)
|
2019-12-11 |
2021-06-17 |
Iovance Biotherapeutics, Inc. |
Procédés pour la production de lymphocytes infiltrant les tumeurs (til) et leurs procédés d'utilisation
|
AU2020402885A1
(en)
|
2019-12-13 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (C9orf72) iRNA agent compositions and methods of use thereof
|
JP2023509373A
(ja)
|
2019-12-20 |
2023-03-08 |
ノヴァロック バイオセラピューティクス, リミテッド |
抗インターロイキン-23 p19抗体およびそれの使用方法
|
EP4085133A1
(fr)
|
2019-12-30 |
2022-11-09 |
Lifeedit Therapeutics, Inc. |
Nucléases guidées par arn et fragments actifs, variants associés et procédés d'utilisation
|
EP4085136A1
(fr)
|
2019-12-31 |
2022-11-09 |
Phio Pharmaceuticals Corp. |
Oligonucléotides chimiquement modifiés présentant une administration systémique améliorée
|
CA3163838A1
(fr)
|
2020-01-08 |
2021-07-15 |
Vipin Suri |
Compositions et procedes pour la regulation accordable de la transcription
|
GB202000934D0
(en)
|
2020-01-22 |
2020-03-04 |
Ucl Business Ltd |
Engineered immune cells
|
WO2021155065A1
(fr)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Éditeurs de bases, compositions, et procédés de modification du génome mitochondrial
|
WO2021154941A1
(fr)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni du composant c5 du complément destinées à être utilisées dans le traitement de la sclérose latérale amyotrophique (sla)
|
US20230108687A1
(en)
|
2020-02-05 |
2023-04-06 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
US20230235309A1
(en)
|
2020-02-05 |
2023-07-27 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
US20230079539A1
(en)
|
2020-02-10 |
2023-03-16 |
Board Of Regents, The University Of Texas System |
Methods for rapid cloning and expression of hla class i cells
|
IL295234A
(en)
|
2020-02-14 |
2022-10-01 |
Merck Sharp & Dohme Llc |
HPV vaccine
|
US11752199B1
(en)
|
2020-02-25 |
2023-09-12 |
Mallinckrodt Ard Ip Unlimited Company |
Methods of modulating pericytes
|
EP4114947A1
(fr)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de composant c3 du complément et leurs procédés d'utilisation pour le traitement ou la prévention de maladies associées au composant c3 du complément
|
EP3885440A1
(fr)
|
2020-03-26 |
2021-09-29 |
Splicebio, S.L. |
Intéines divisées et leurs utilisations
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
EP4133077A1
(fr)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de la serine protease 2 transmembranaire (tmprss2) et leurs procédés d'utilisation
|
WO2021206917A1
(fr)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions arni d'enzyme de conversion de l'angiotensine 2 (eca2) et procédés d'utilisation associés
|
TW202208626A
(zh)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna引導核酸酶及其活性片段與變體,以及使用方法
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
WO2021222318A1
(fr)
|
2020-04-28 |
2021-11-04 |
The Broad Institute, Inc. |
Édition de base ciblée du gène ush2a
|
WO2021226061A1
(fr)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
|
CN111393595A
(zh)
*
|
2020-05-06 |
2020-07-10 |
东莞市竤穗实业投资有限公司 |
一种具有温敏特性的生物基聚碳化二亚胺交联剂及其制备方法
|
US20230212613A1
(en)
|
2020-05-06 |
2023-07-06 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
AU2021269103A1
(en)
|
2020-05-06 |
2022-12-15 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
CA3177481A1
(fr)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methodes et compositions d'edition simultanee des deux brins d'une sequence nucleotidique double brin cible
|
WO2021231437A1
(fr)
|
2020-05-11 |
2021-11-18 |
LifeEDIT Therapeutics, Inc. |
Protéines de liaison d'acide nucléique guidées par arn, fragments et variants actifs associés et procédés d'utilisation
|
CA3162416C
(fr)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Procedes et compositions pour l'edition mediee par adar d'argininosuccinate synthetase (ass1)
|
EP4150090A1
(fr)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Procédés et compositions pour l'édition médiée par adar d'otoferline (otof)
|
EP4150076A1
(fr)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Procédés et compositions pour l'édition médiée par adar de la protéine 2 de liaison méthyl-cpg (mecp2)
|
EP4150077A1
(fr)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Procédés et compositions pour l'édition médiée par adar de la protéine 1 de type canal transmembranaire (tmc1)
|
EP4150086A1
(fr)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Procédés et compositions pour l'édition médiée par adar de la kinase 2 à répétition riche en leucine (lrrk2)
|
WO2021231691A1
(fr)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Procédés et compositions pour l'édition médiée par adar de rétinoschisine 1 (rs1)
|
WO2021231698A1
(fr)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Procédés et compositions pour l'édition médiée par adar d'argininosuccinate lyase (asl)
|
WO2021231679A1
(fr)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Procédés et compositions pour l'édition médiée par adar de la protéine bêta 2 de jonction lacunaire (gjb2)
|
EP4153210A2
(fr)
|
2020-05-19 |
2023-03-29 |
Othair Prothena Limited |
Vaccins à multiples épitopes pour le traitement de la maladie d'alzheimer
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4162050A1
(fr)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni et leurs procédés d'utilisation pour une administration par inhalation
|
WO2022011262A1
(fr)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Méthodes et compositions pour le traitement de l'épilepsie
|
AU2021310363A1
(en)
|
2020-07-15 |
2023-03-16 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
AU2021316727A1
(en)
|
2020-07-30 |
2023-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immune cells defective for SOCS1
|
WO2022034374A2
(fr)
|
2020-08-11 |
2022-02-17 |
University Of Oslo |
Édition génique améliorée
|
EP4204545A2
(fr)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
Lymphocytes t à fonctionnalité améliorée
|
EP4208259A2
(fr)
|
2020-09-04 |
2023-07-12 |
NovaRock Biotherapeutics, Ltd. |
Anticorps anti-nectine-4 et leurs utilisations
|
JP2023541418A
(ja)
|
2020-09-10 |
2023-10-02 |
モンサント テクノロジー エルエルシー |
減数分裂及び生殖系列プロモーターを使用する遺伝子編集及び部位特異的組込み事象の増加
|
WO2022056254A2
(fr)
|
2020-09-11 |
2022-03-17 |
LifeEDIT Therapeutics, Inc. |
Enzymes modifiant l'adn et fragments actifs et variants de celles-ci et procédés d'utilisation
|
US20230348892A1
(en)
|
2020-09-17 |
2023-11-02 |
Northwestern University |
Engineered mamalian genetic circuits and methods of using the same
|
WO2022066847A1
(fr)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de dipeptidyle peptidase 4 (dpp4) et leurs procédés d'utilisation
|
EP3973978A1
(fr)
|
2020-09-25 |
2022-03-30 |
Mallinckrodt Ard IP Unlimited Company |
Procédés de modulation de la réponse d'un corticostéroïde
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
WO2022076606A1
(fr)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs
|
CA3195019A1
(fr)
|
2020-10-06 |
2022-04-14 |
Maria Fardis |
Traitement de patients souffrant de cpnpc avec des therapies de lymphocytes infiltrant les tumeurs
|
EP4229074A1
(fr)
|
2020-10-16 |
2023-08-23 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Immunité antitumorale induisant la présentation de peptides aberrants
|
CA3198823A1
(fr)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methodes et compositions pour le traitement de l'hyperoxalurie primaire
|
EP4232582A1
(fr)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de la mucine 5b (muc5b) et leurs méthodes d'utilisation
|
US11591544B2
(en)
|
2020-11-25 |
2023-02-28 |
Akagera Medicines, Inc. |
Ionizable cationic lipids
|
CA3201452A1
(fr)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methodes et compositions pour l'inhibition de l'expression du gene de l'hao1 (hydroxyacide oxydase 1 (glycolate oxydase))
|
WO2022133140A1
(fr)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Traitement avec des thérapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de ctla-4 et de pd-1
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
WO2022150790A2
(fr)
|
2021-01-11 |
2022-07-14 |
The Broad Institute, Inc. |
Variants d'éditeur primaire, constructions et procédés pour améliorer l'efficacité et la précision d'une édition primaire
|
WO2022164796A1
(fr)
|
2021-01-26 |
2022-08-04 |
California Institute Of Technology |
Arn guides conditionnels allostériques pour la régulation sélective de cellules de crispr/cas
|
WO2022164319A1
(fr)
|
2021-01-29 |
2022-08-04 |
Wageningen Universiteit |
Édition de bases associée à crispr du brin complémentaire
|
EP4288447A1
(fr)
|
2021-02-03 |
2023-12-13 |
Altria Client Services LLC |
Augmentation de la densité de trichomes et amélioration du transport de métabolites dans des trichomes végétaux
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
KR20230146048A
(ko)
|
2021-02-12 |
2023-10-18 |
알닐람 파마슈티칼스 인코포레이티드 |
슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
|
EP4298220A1
(fr)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions à base d'arni de protéine prion (prnp) et procédés et procédés d'utilisation de celles-ci
|
WO2022192789A1
(fr)
|
2021-03-12 |
2022-09-15 |
Synthego Corporation |
Cellules génétiquement modifiées exprimant des protéines de fusion contenant des antigènes et leurs utilisations
|
EP4305169A1
(fr)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de la glycogène synthase kinase 3 alpha (gsk3a) et leurs procédés d'utilisation
|
EP4314266A1
(fr)
|
2021-03-22 |
2024-02-07 |
Lifeedit Therapeutics, Inc. |
Enzymes de modification de l'adn et fragments actifs et variants associés et méthodes d'utilisation
|
KR20230162024A
(ko)
|
2021-03-29 |
2023-11-28 |
알닐람 파마슈티칼스 인코포레이티드 |
헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법
|
WO2022225981A2
(fr)
|
2021-04-19 |
2022-10-27 |
Iovance Biotherapeutics, Inc. |
Récepteurs costimulateurs chimériques, récepteurs de chimiokines et leur utilisation dans des immunothérapies cellulaires
|
AU2022261124A1
(en)
|
2021-04-22 |
2023-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
WO2022245583A1
(fr)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de cotransporteur-2 de sodium-glucose (sglt2) et leurs procédés d'utilisation
|
EP4341405A1
(fr)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Procédés et compositions pour l'édition médiée par adar
|
JP2024519041A
(ja)
|
2021-05-21 |
2024-05-08 |
セレクティス ソシエテ アノニム |
固形腫瘍における癌関連線維芽細胞を調節することによるt細胞媒介性免疫療法の効力の増強
|
WO2022256283A2
(fr)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Méthodes de restauration de la fonction protéique par adar
|
BR112023025224A2
(pt)
|
2021-06-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
|
EP4352215A1
(fr)
|
2021-06-11 |
2024-04-17 |
LifeEDIT Therapeutics, Inc. |
Promoteurs d'arn polymérase iii et procédés d'utilisation
|
WO2022261509A1
(fr)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Éditeurs de bases cytosine à guanine améliorés
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(fr)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Procédés et compositions pour édition médiée par adar
|
US20230044997A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
US20230042860A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
US20230046606A1
(en)
|
2021-07-15 |
2023-02-16 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
GB202110646D0
(en)
|
2021-07-23 |
2021-09-08 |
Sisaf Ltd |
Nucleic acid vector compositions
|
GB202110644D0
(en)
|
2021-07-23 |
2021-09-08 |
Sisaf Ltd |
Improved nucleic acid vector particles
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
EP4377446A1
(fr)
|
2021-07-28 |
2024-06-05 |
Iovance Biotherapeutics, Inc. |
Traitement de patients atteints d'un cancer avec des thérapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de kras
|
CN118043459A
(zh)
|
2021-08-04 |
2024-05-14 |
菲奥医药公司 |
经化学修饰的寡核苷酸
|
WO2023015264A1
(fr)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunothérapie anticancéreuse utilisant des cellules tueuses naturelles traitées avec des oligonucléotides chimiquement modifiés
|
WO2023015309A2
(fr)
|
2021-08-06 |
2023-02-09 |
The Broad Institute, Inc. |
Éditeurs primaires améliorés et leurs procédés d'utilisation
|
WO2023023152A1
(fr)
|
2021-08-19 |
2023-02-23 |
Merck Sharp & Dohme Llc |
Nanoparticule lipidique thermostable et ses méthodes d'utilisation
|
CA3233460A1
(fr)
|
2021-10-01 |
2023-04-06 |
Jeroen Petrus Wilhelmus Maria BAKKERS |
Regeneration cardiaque de mammifere
|
CA3235867A1
(fr)
|
2021-10-22 |
2023-04-27 |
Munir MOSAHEB |
Composition de vaccin a base d'arnm
|
CA3234835A1
(fr)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Procedes et compositions pour perturber l'interaction de la proteine nrf2-keap1 par l'edition d'arn a mediation adar
|
WO2023076898A1
(fr)
|
2021-10-25 |
2023-05-04 |
The Broad Institute, Inc. |
Procédés et compositions pour l'édition d'un génome à l'aide d'une édition primaire et d'une recombinase
|
WO2023077015A2
(fr)
|
2021-10-27 |
2023-05-04 |
Iovance Biotherapeutics, Inc. |
Systèmes et méthodes pour coordonner la fabrication de cellules pour l'immunothérapie spécifique d'un patient
|
WO2023076450A2
(fr)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'agent d'arni de la huntingtine (htt) et leurs procédés d'utilisation
|
WO2023077148A1
(fr)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Plateforme de construction unique pour administration simultanée d'une machinerie d'édition de gène et d'une cargaison d'acide nucléique
|
CN114015674A
(zh)
|
2021-11-02 |
2022-02-08 |
辉二(上海)生物科技有限公司 |
新型CRISPR-Cas12i系统
|
WO2023080788A1
(fr)
|
2021-11-05 |
2023-05-11 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Déplétion de tryptophane induisant la production et la présentation de tryptophane à des substitutions de phénylalanine
|
CA3237410A1
(fr)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Procedes de traitement de multiplication utilisant des lymphocytes infiltrant les tumeurs cd8
|
WO2023096858A1
(fr)
|
2021-11-23 |
2023-06-01 |
Senda Biosciences, Inc. |
Composition lipidique dérivée de bactéries et son utilisation
|
WO2023096494A1
(fr)
|
2021-11-26 |
2023-06-01 |
Synvolux Ip B.V. |
Épitopes de lymphocytes t de coronavirus conservés
|
WO2023122080A1
(fr)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprenant de l'arnm et des paquets de messagers végétaux reconstruits lipidiques
|
WO2023122762A1
(fr)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation de la transcription génique à l'aide d'oligonucléotides antisens ciblant des arn régulateurs
|
WO2023122764A1
(fr)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-administration d'une construction d'éditeur génique et d'un patron donneur
|
WO2023126458A1
(fr)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Cellules immunitaires avec suv39h1 inactivé et tcr modifié
|
WO2023139557A1
(fr)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Nucléases guidées par arn et fragments actifs, variants associés et procédés d'utilisation
|
WO2023141314A2
(fr)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'agent d'arni d'enzyme de voie de biosynthèse de sulfate d'héparine et leurs méthodes d'utilisation
|
WO2023150637A1
(fr)
|
2022-02-02 |
2023-08-10 |
Inscripta, Inc. |
Protéines de fusion de nickase guidées par un acide nucléique
|
WO2023196802A1
(fr)
|
2022-04-04 |
2023-10-12 |
The Broad Institute, Inc. |
Variantes de cas9 ayant des spécificités pam non canoniques et leurs utilisations
|
WO2023196818A1
(fr)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Compositions et procédés de complémentation génétique
|
WO2023196851A1
(fr)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Inversion du vieillissement du système nerveux central
|
WO2023201369A1
(fr)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Processus d'expansion de til utilisant des combinaisons spécifiques de cytokine et/ou traitement akti
|
WO2023205744A1
(fr)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Compositions d'insertion de gènes programmable
|
WO2023212715A1
(fr)
|
2022-04-28 |
2023-11-02 |
The Broad Institute, Inc. |
Vecteurs aav codant pour des éditeurs de base et utilisations associées
|
WO2023215831A1
(fr)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Compositions d'arn guide pour insertion de gène programmable
|
WO2023220603A1
(fr)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vecteurs et procédés de production d'anticorps in vivo
|
WO2023220457A1
(fr)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Amélioration, médiée par le recrutement de récepteurs, de l'administration de produits biologiques
|
WO2023220392A1
(fr)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Capteurs extracellulaires modulaires synthétiques utilisant des domaines de liaison à un ligand de récepteur naturel
|
WO2023220459A1
(fr)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Chargement actif d'une entité cargo dans des particules de bicouche lipidique à l'aide de domaines de dimérisation
|
EP4279085A1
(fr)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions et procédés de traitement d'un cancer réfractaire ou récurrent ou d'une maladie infectieuse chronique
|
WO2023225670A2
(fr)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Insertion de gène programmable ex vivo
|
WO2023230433A1
(fr)
|
2022-05-23 |
2023-11-30 |
Altria Client Services Llc |
Procédés et compositions pour la régulation des alcaloïdes dans le domaine du tabac
|
WO2023230613A1
(fr)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Éditeurs de base mitochondriale améliorés et méthodes d'édition d'adn mitochondrial
|
WO2023235818A2
(fr)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Systèmes crispr de type v, classe 2, modifiés
|
WO2023235392A1
(fr)
|
2022-06-02 |
2023-12-07 |
Perkinelmer Health Sciences, Inc. |
Caractérisation médiée par électrophorèse de la teneur en adn de capsides de virus adéno-associés
|
EP4314267A1
(fr)
|
2022-06-07 |
2024-02-07 |
Scribe Therapeutics Inc. |
Compositions et procédés pour le ciblage de pcsk9
|
WO2023240074A1
(fr)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions et procédés pour le ciblage de pcsk9
|
WO2023240137A1
(fr)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Variants de cas14a1 évolués, compositions et méthodes de fabrication et d'utilisation de ceux-ci dans l'édition génomique
|
WO2023240277A2
(fr)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Méthodes de modulation de l'expression de progranuline à l'aide d'oligonucléotides antisens ciblant des arn régulateurs
|
CN116444395A
(zh)
*
|
2022-06-27 |
2023-07-18 |
上海云沂生物医药科技有限公司 |
一种氨基脂质、其合成方法、颗粒及用途
|
WO2024003334A1
(fr)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Amélioration de la sécurité de l'immunothérapie à médiation par les lymphocytes t
|
WO2024015383A1
(fr)
|
2022-07-12 |
2024-01-18 |
Northwestern University |
Biocapteurs d'hypoxie modifiés et leurs procédés d'utilisation
|
WO2024020587A2
(fr)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Insertion de gènes programmable par des cellules souches pléiopluripotentes
|
WO2024026474A1
(fr)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions et méthodes d'administration médiée par le récepteur de la transferrine (tfr) au cerveau et au muscle
|
US20240132901A1
(en)
|
2022-08-05 |
2024-04-25 |
Altria Client Services Llc |
Methods and compositions for regulating alkaloids in tobacco
|
WO2024033901A1
(fr)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Nucléases guidées par arn et fragments actifs, variants associés et procédés d'utilisation
|
WO2024040083A1
(fr)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Cytosine désaminases évoluées et méthodes d'édition d'adn l'utilisant
|
WO2024042489A1
(fr)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Modification chimique d'arn guides avec un acide nucléique verrouillé pour l'édition de gènes à médiation par nucléase guidée par l'arn
|
WO2024047587A1
(fr)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Compositions cas-phi et méthodes d'utilisation
|
WO2024059165A1
(fr)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
|
WO2024094775A1
(fr)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Amélioration de l'efficacité et de la sécurité de l'immunothérapie médiée par lymphocytes t
|
WO2024098024A1
(fr)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion de lymphocytes infiltrant les tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
|
WO2024098002A1
(fr)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Protéines de liaison de sous-unité auxiliaire gamma 1 du canal calcique dépendant de la tension (cacng1) et administration médiée par cacng1 au muscle squelettique
|
WO2024095245A2
(fr)
|
2022-11-04 |
2024-05-10 |
LifeEDIT Therapeutics, Inc. |
Désaminases d'adénine évoluées et protéines de fusion de nucléase guidée par arn avec des sites d'insertion internes et procédés d'utilisation
|
WO2024102434A1
(fr)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Compositions d'arn comprenant des nanoparticules lipidiques ou des packs de messagers naturels reconstitués en packs lipidiques
|
WO2024107765A2
(fr)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions et procédés d'administration médiée par le récepteur 3 du facteur de croissance des fibroblastes à des astrocytes
|